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Abstract 
 
Cell division cycle 25 (CDC25) proteins are highly conserved dual specificity 
phosphatases that regulate the proper advancement of the cell cycle by activation of 
CDK/cyclin complexes. Overexpression of CDC25s, resulting in genomic instability 
and dysregulated cell growth, is frequently related to aggressiveness, high-grade tumors 
and poor prognosis. Thus, this family of enzymes represent an attractive target for drug 
discovery. Recently, compound 11, 3-(4,5,6-trihydroxy-3-oxo-3H-xanthen-9-yl)-
propanoic acid, and compound 19, 4-(2-carboxybenzoyl)phthalic acid, were identified 
as novel inhibitors of CDC25s with a different inhibition profile, by using a structure-
based virtual screening approach. Both compounds arrested cells at the G0/G1 and G2/M 
phases of the cell cycle, increased Cdk1 hyperphosphorylation in K562 leukemia cells, 
and significantly suppressed the growth of human MCF-7 breast, PC-3 prostate cancer 
lines as well as K562 leukemia cells, thus representing novel interesting leads. This 
thesis project focused on the computer-assisted lead optimization of the initial hits 11 
and 19. Firstly, in order to expand our understanding of structure-activity relationships 
within the 6-xanthone class of CDC25 inhibitors, we identified a series of structural 
analogs of compound 11 by ligand-based chemoinformatic approach. We examined 
their activity against melanoma cancer cell lines, as well as the mechanism of action 
involved. Nine compounds (3, 5–9, 21, 24, and 25) were identified with Ki values for 
CDC25A, -B and -C ranging from 0.01 to 4.4 μM. One of these analogs, 7, showed a 
high antiproliferative effect on human melanoma cell lines, A2058 and SAN, associated 
with an arrest in G2/M phase of the cell cycle. Furthermore, 7 induced apoptosis 
through intrinsic pathway. Interestingly, compound 7 decreased the protein levels of 
phosphorylated Akt and increased those of p53, thus contributing to the regulation of 
chemosensitivity through the control of downstream Akt pathways in melanoma cells. 
Secondly, a series of novel derivatives of compound 19 was rationally designed by 
using a structure-based approach, guided by preliminary docking studies, with the aim 
to improve its binding affinity, pharmacokinetic properties as well as to investigate its 
anti-melanoma effect. A focused library of 24 derivatives was synthesized: a 
preliminary screening of the inhibitory activities toward CDC25B showed that ten 
ii 
 
molecules (compounds 2, 3d, 4, 4a, 4b, 5f, 6, 6a, 6b, 7) acted as powerful inhibitors 
with Ki values ranging between 2.8–20.1 µM. Among them, compounds 2 and 6a 
showed good antiproliferative effects on melanoma cell line A2058. Taken together, our 
data emphasize that CDC25 could be considered as a possible oncotarget in melanoma 
cells and that the designed compounds represent small molecule CDC25 inhibitors that 
merit to be further evaluated as chemotherapeutic agents for melanoma, likely in 
combination with other therapeutic compounds. 
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1. Introduction 
 
1.1 Protein phosphatases 
 
The reversible phosphorylation of proteins represents a fundamental mechanism 
in eukaryotic signaling, with up to 30% of all proteins being phosphorylated at any 
given time [1]. Many biological functions are regulated through this mechanism 
including DNA replication, cell cycle progression, energy metabolism, cell 
differentiation and development [2-3]. Levels of cellular protein phosphorylation are 
controlled by protein kinases, which catalyze the formation of phosphate ester bonds, 
and protein phosphatases, which catalyze phosphate ester hydrolysis. Because of this 
broad spectrum in activity, it is not surprising that malfunctions of PTPs are associated 
with various diseases, for example neurological disorders, diabetes, or cancer [4]. 
Protein phosphatases evolved from diverse ancestors, resulting in different domain 
architectures, reaction mechanisms and active site properties. In humans, protein 
phosphorylation predominantly occurs on tyrosine, serine and threonine residues with 
phosphoserine accounting for most of the phosphorylated sites (86.4%), followed by 
threonine (11.2%) and finally tyrosine being the least abundant (1.8%) [5]. Two distinct 
families of protein phosphatases are known: the serine/threonine phosphatases, which 
dephosphorylate substrates in a single-step reaction via a metal-activated water 
molecule and the protein tyrosine phosphatases (PTPs), which dephosphorylate 
phosphotyrosine in a two-step reaction [6-9]. PTPs also include a subfamily of dual-
specificity protein tyrosine phosphatases (DSPs), which hydrolyze both tyrosine and 
serine/threonine phosphoesters [9], and thereby play important roles in regulating 
various intracellular activities and mechanisms associated with human diseases [10]. 
The cell division cycle 25 (CDC25) phosphatases are a subfamily of DSPs that are vital 
to cell cycle regulation via the activation of CdK/cyclin complexes. 
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1.1.1 Structure and function of CDC25 
 
CDC25 was first identified in the fission yeast Saccharomyces pombe as the 
twenty-fifth protein that regulated the cell-division cycle [11]. CDC25 phosphatases are 
found in all eukaryotic organisms except plants [12]. Three isoforms have been 
identified in humans: CDC25A, CDC25B and CDC25C [13-15]. CDC25A, -B and -C 
contain 524, 580 and 473 amino acids, respectively, resulting in molecular masses in the 
53–65 kDa range [16]. The three human CDC25 isoforms, although sharing functional 
and sequence homology, are encoded by unique genes that localize to three different 
chromosomes: CDC25A is found on 3p21, CDC25B on 20p13 and CDC25C on 5q31 
[17]. CDC25 proteins are structurally divided into two principal domains: an N-terminal 
regulatory domain and a C-terminal catalytic domain. The C-terminal catalytic domains 
are highly similar between all three proteins, with approximately 60% sequence identity 
between any of the family members.  The regulatory domains vary widely between the 
three proteins, with multiple splice variants being reported: at least two for CDC25A, 
five for CDC25B and five for CDC25C [18-21]. The N-terminal domain of the CDC25 
proteins contains a nuclear export signal (NES) and a nuclear localization signal (NLS), 
as well as many phosphorylation sites involved in the regulation of the activity, protein 
stability and the association with regulatory partners [22]. The carboxy-terminal domain 
contains the canonical PTPase active site motif HCX5R: H is a highly conserved 
histidine residue, C is the catalytic cysteine, X5 are five residues that form a loop in 
which all of the amide hydrogen molecules are bound to the phosphate of the substrate, 
and R is a highly conserved arginine required for binding to the phosphorylated amino 
acid of the substrate.  The crystal structures of the catalytic domains of CDC25A and 
CDC25B have been reported at 2.3 Å and 1.9 Å resolution, respectively, but no crystal 
structure for the full-length protein is available. Examination of the structure of CDC25s 
has revealed that, in contrast to other protein phosphatases, their active site is 
surprisingly flat and extremely shallow, with a lack of auxiliary loops and no obvious 
features for mediating substrate recognition, which suggests a broad protein interface 
[23-24]. Indeed, substrate recognition has been proposed to rely on hotspot residues 
(R488, R492 and Y497 on CDC25B) located 20-30 Å from the active site [25-26]. 
Although the overall structures of the two CDC25 catalytic domains are similar, the 
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catalytic site of CDC25A failed to bind oxyanions, while that of CDC25B readily bound 
tungstate and sulphate in a mode similar to other PTP- and DSPases [24]. The CDC25A 
catalytic domain also lacks any flexible peptide loops proximal to the active site that 
might facilitate substrate binding [23-24]. One of the largest cavities on the surface of 
CDC25B is adjacent to the catalytic pocket and is known as the “swimming pool”, for 
the abundance of well-ordered water molecules contained within the pocket [27]. Key 
differences between the CDC25B and CDC25A catalytic domains are located in the C 
terminus (residues 531–547 in CDC25B numbering). The carboxy-terminal tail of 
CDC25B folds back on its active site, whereas the carboxy-terminal tail of CDC25A is 
directed away from the active site cleft, which results in a more open structure (Figure 
1).  
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CDC25s utilize a two-step reaction for phosphate monoester hydrolysis, as shown in 
Figure 2 [28]. The first step is the nucleophilic attack from a PTP cysteine side chain 
toward the phosphate ester substrate, with a possible H+ transfer from a general acid to 
the leaving group. A thiophosphorylated-PTP intermediate is formed, and the 
dephosphorylated substrate dissociates from the active site cavity. In the second reaction 
step the PTP intermediate is hydrolyzed, whereby the phosphate group is released and 
free enzyme is regenerated [25,29].  
 
Figure 1. Structures and domains of CDC25A and CDC25B. A) Surface view of 
CDC25A (palegreen). The catalytic site is indicated in blue marine. The C-terminal 
tail (residues 484-495) is shown in palegreen cartoon. B) Surface view of CDC25B 
(blue marine). The catalytic site and the adjacent “swimming pool” pocket are 
indicated in palegreen. The water molecules are represented as red spheres. The
hotspot residues (R488, R492 and Y497), which govern the association with the
protein substrate, are shown in blue sticks. The remote hotspot region is highlighted in
palegreen. The α-helical C-terminal tail (residues 531–550) is shown in palegreen 
cartoon [16]. 
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Figure 2. Catalytic cycle for cysteine-based PTPs. Adapted from [28]. 
 
Almost all PTPs use as a general acid, an Asp residue located in a mobile loop 
(the WPD loop) [29]. CDC25s lack an analogous catalytic acid residue near the active 
site or in a flexible loop that could donate a H+ to the leaving group [23-24]. Hence, the 
identity of the general acid on CDC25s remains vague. It has been suggested that the 
catalytic acid is an E residue (E474 on CDC25B) located in the active site just after the 
catalytic cysteine (C473 on CDC25B) [23,30]. This E residue is conserved among all 
known CDC25 isoforms [29]. However, Chen et al. proposed that the putative catalytic 
acid residue may instead be located on the protein substrate rather than on CDC25B 
[31]. Another proposal suggested that the substrate could bind as a phosphate 
monoanion rather than dianion and transfer the proton itself to the leaving group [32]. 
This latter mechanism has been recently supported by Rudolph and co-workers through 
QM/MM minimum free energy path calculations [33]. 
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1.1.2 CDC25 in cell cycle regulation 
 
Progression through the cell cycle is regulated by the action of Cyclin/Cyclin 
dependent kinase (CDK) complexes. These latter are held inactive by the 
phosphorylation of two residues (Threonine 14 and Tyrosine 15 on CDK1) by the 
WEE1 and MYT1 kinases. When CDK activity becomes required for cell cycle 
progression, the CDC25s dephosphorylate these two residues, thereby activating the 
CDK-Cyclin complexes [34]. CDC25A is predominantly found in nucleus [35], 
whereas the other two isoforms shuttle in and out the nucleus throughout cell cycle 
progression [36-37]. It is believed that all three isoforms are essential for the proper 
execution of the cell cycle, although it has been shown that CDC25A alone is sufficient 
for initiation of each step in the cycle [37-38]. A simplified overview of the cell cycle 
regulation is shown in Figure 3.  
 
 
 
Figure 3. An overview of the regulatory function of CDC25s in cell cycle progression [16]. 
 
At G0-phase, the CDK3/cyclin C complex initiates the re-entry of quiescent cells 
into the cell cycle. In middle G1-phase, CDC25A activates CDK4 and CDK6 that are in 
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complex with cyclin D [39]. CDC25A reaches its highest expression level at late G1-
phase during which, in combination with CDC25B, it facilitates the transition into S-
phase by dephosphorylation of CDK2/cyclin A [40]. CDC25C controls the initiation of 
the S-phase [41]. At late S-phase, CDC25B dephosphorylates CDK1/cyclin A, a less 
active complex compared to CDK2/cyclin A, which persists throughout G2-phase [40]. 
All three CDC25 isoforms are involved in the G2/M-transition but CDC25B appears to 
take the key role in this process [42]. Infact, CDC25B is most abundant and active at 
late G2-phase and during mitosis, and is localized to the centrosome where it 
dephosphorylates CDK1/cyclin B [42-43]. This latter is subsequently translocated to the 
nucleus, where it is completely activated by CDC25C leading to mitotic onset [40]. At 
the end of mitosis, both CDK1/cyclin B and the CDC25s are degraded resulting in 
transition into interphase. The proteins are subjected to anaphase promoting 
complex/cyclosome (APC/C)-dependent ubiquitination leading to proteasome-mediated 
degradation [44].  
 
1.1.3 Control of CDC25 expression and activity 
 
CDC25 phosphatase activities are highly regulated by multiple mechanisms, 
including inhibitory and activating phosphorylations, changes in intracellular 
localization and interactions with partner proteins. Phosphorylation of the N-terminal 
regulatory domains by several kinases, including the CDK/cyclin complexes 
themselves, has been reported to regulate the activities of the CDC25 phosphatases 
[22,45]. Two other important kinases positively regulate CDC25s and promote mitosis: 
the polo-like kinase 1 (PLK1) and Aurora kinases. The former activates CDC25C both 
directly and indirectly by CDK1/cyclin B phosphorylation and inhibition of the Wee1-
like kinase Myt1 [46], in addition to favoring the nuclear import of CDC25C [47], 
whereas the latter activates both PLK1 and CDC25s [48-49]. PLK1 also plays a role in 
mitotic exit, as it is a positive regulator of the APC/C activity [50]. Phosphorylation has 
also been reported to influence the ability of the CDC25s to interact with 14-3-3 
proteins, which function to retain proteins in various subcellular compartments [17]. At 
the transcription level, CDC25s are activated by the transcription factors E2F1, E2F2 
and E2F3, the antagonists of Rb. Signal transducer and activator of transcription 3 
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(STAT3) usually activates CDC25 gene transcription, but through Rb recruitment it can 
also exhibit an inhibitory effect [51]. The transcription factor p53, which regulates the 
expression of genes impinging on cell cycle arrest, was reported to be responsible of the 
transcriptional repression of the three CDC25 phosphatases [52-53]. 
1.1.4 Cell cycle checkpoints 
 
Multiple checkpoint pathways are activated in response to DNA damage or 
environmental insults in order to block the cell cycle progression. At the G1/S 
checkpoint, DNA synthesis is inhibited, whereas intra-S phase arrest blocks mitotic 
entry until the S-phase is completed [40]. Finally, at the G2/M checkpoint, damaged 
cells are arrested in order to allow for cell repair or apoptosis [54]. CDC25s are 
inactivated by checkpoint kinases (CHK1 and CHK2) in an ataxia-telangiectasia 
mutated (ATM) and AT and Rad3-related (ATR) kinases-dependent manner. Upon 
DNA single-strand damage, ATR activates CHK1, whereas ATM activates CHK2 and 
the tumor suppressor protein p53 mainly as a result of double-strand breaks [47,55]. 
Activated CHK1/CHK2 target CDC25 leading to its inhibition or degradation. The 
checkpoint kinases also increase the amount of Wee1 resulting in inactivation of CDKs 
[55], and the CDC25 activator PLK1 appears to be inhibited in an ATM/ATR-
CHK1/CHK2-dependent manner. In detail, CHK2 inhibits CDC25A through p53 [56] 
resulting in inactivation of CDK4/cyclin D and CDK2/cyclin E, thus blocking S-phase 
entry [56-57]. On the other hand, all three isoforms of CDC25 are phosphorylated by 
CHK1 in order to prevent mitotic onset. Phosphorylated CDC25A/B can no longer 
activate CDK1/cyclin B [58-59], and inactivation of CDC25B/C sequesters the proteins 
in the cytoplasm [60-61]. Also, hyperphosphorylation of CDC25A leads to its 
degradation [58,62]. The checkpoints are silenced after repair or degradation of the 
damaged cells [54], and the re-entry into mitosis upon DNA-damage arrest is controlled 
by CDC25B upon activation by PLK1 [63]. PLK1 also inactivates CHK1 by mediated 
degradation of Claspin, the adaptor and activating partner of CHK1 [64]. In addition to 
the checkpoint kinases, several other proteins are involved in CDC25 inhibition, for 
example protein kinase B (PKB/Akt) and mitogen-activated protein kinases (MAPKs). 
The latter negatively regulate CDC25 upon DNA damage mediated by heat shock, 
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oxidative stress, irradiation, feed deprivation and chemotherapy [40,65]. The effects of 
the PI3K-Akt-mTOR pathway on cell cycle progression are not completely understood 
and conflicting results have been obtained. On one side, Akt sequesters CDC25s in the 
cytoplasm upon binding to protein 14-3-3, thus inhibiting mitosis [66]. Also, it seems as 
if CDC25B activity itself is required for the activation of Akt and the p38 MAPK kinase 
[67], thus indicating a mutual regulation of these proteins. On the contrary, several 
studies have shown that Akt acts as an initiator of mitosis [68-69] and inactivation of 
both CHK1 [70] and CHK2 [71] by Akt have been observed, thus circumventing the 
degradation of CDC25s. Following DNA damage for instance, Akt impairs the 
activation of CHK1 in an ATR-independent manner, thus circumventing the cell cycle 
checkpoint and inhibiting apoptosis [72]. In concordance with this, inhibition of Akt led 
to restored CHK1 activity [73]. 
 
1.1.5 CDC25 phosphatases as therapeutic targets  
As detailed above, CDC25 phosphatases must be tightly regulated throughout the 
cell division cycle to maintain the precise spatial and temporal level of CDK–cyclin 
activities. In addition, CDC25 phosphatases must be inactivated in response to 
checkpoint activation to stop cell cycle progression and allow the cell to either repair the 
DNA or initiate apoptosis [47]. Misregulation of these processes can contribute to 
genomic instability. Dysregulation in the case of CDC25A, for example, accelerates the 
G1/S-phase transition [74], whereas an overexpression of CDC25B leads to premature 
mitotic entry [75]. Elevated levels of CDC25A and CDC25B have been noted in many 
human tumor types, such as breast, ovarian, prostate, lung, colorectal, oesophageal, 
thyroid, laryngeal, hepatocellular, gastric, pancreatic, endometrial, head and neck 
cancer, neuroblastoma, glioma and non-Hodgkin lymphoma [22], where there seems to 
be a remarkable association with high protein levels and either tumor aggressiveness or 
poor prognosis [17,76-77]. CDC25A and CDC25B have been reported to transform 
cells in cooperation with the RAS oncogene or in the absence of the retinoblastoma 
tumor suppressor protein [78]. CDC25A and B are also transcriptional targets of the c-
MYC oncogene, and have oncogenic properties in cooperation with either Ha-RAS or 
Rb1 [79]. The involvement of CDC25A in the adhesion-dependent proliferation of acute 
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myeloid leukaemia (AML) cells has also been described [80]. CDC25A and CDC25B 
have also been observed to be highly expressed in the brains of patients with 
Alzheimer’s disease and may contribute to the pathology of neurodegeneration [81-82]. 
With regard to CDC25C, only a few studies showed an overexpression of this form in 
cancers [83-84]. However, growing evidence suggests that the overexpression of 
CDC25C could be underrated because of the non-consideration of its alternative 
splicing [85-86]. Although the mechanism by which CDC25s become overexpressed is 
poorly understood, their expression may be elevated by increased gene expression, 
increased protein stability as a result of deficiencies in protein turnover, or both 
[17,62,87-88]. There is currently no evidence that CDC25 overexpression results from 
gene amplification or rearrangements or any other specific genetic mutations that may 
be responsible for deregulating CDC25 phosphatase activities in cancer [47]. In 
addition, the lack of significant correlation between transcript and protein levels 
suggests that the CDC25 phosphatases can become misregulated at any stage between 
transcription and translation, even at the post-translational level [47]. Given their critical 
role, CDC25s constitute attractive targets for drug discovery. 
 
1.1.6 CDC25 inhibitors  
Strategies to identify small molecule inhibitors of CDC25s generally followed the 
approaches used for other PTPs [89]. Either low or high throughput screens have been 
developed using recombinant protein with a variety of small molecule substrates 
including p-nitrophenyl phosphate, 6,8-difluoro-4-methylumbelliferyl phosphate, 
fluorescein diphosphate or O-methyl-fluorescein phosphate [89]. 
Until the mid-1990s, the only readily available inhibitor was the broad-spectrum 
PTP inhibitor sodium orthovanadate [17]. Natural products have been a rich source of 
inhibitors and a good starting point for the development of synthetic analogues. 
Representative members in this group include the natural products dnacin B1 [90], 
dysidiolide [91], menadione [92], sulfircin [93] and coscinosulfate [94], which inhibit 
the CDC25 family with IC50 values in the 1–10 μM range (Figure 4). 
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Figure 4. Structures of natural product CDC25 inhibitors. 
 
The biological activities of these natural products inspired total syntheses as well 
as the preparation of synthetic analogs and chemical libraries. Synthetic inhibitors 
belong to various chemical classes including phosphate bioisosteres, electrophilic 
entities, and quinonoids. These compounds act via reversible inhibition with the active 
site of CDC25s [95-101], irreversible inhibition of CDC25s by electrophilic 
modification [102-103] or oxidation of the cysteine residue in the catalytic domain 
(HCX5R) to sulfinic (Cys-SO2-) or sulfonic (Cys-SO3-) acid by reactive oxygen species 
(ROS) [104-105] (Figure 5). The number of potent inhibitors of CDC25 phosphatases 
that efficiently inhibit the proliferation of cancer cells and that are active in vivo on 
xenografted human tumors is quite limited. Compounds BN82002 [106] and BN82685 
[107] impaired the growth of MiaPaCa human pancreatic carcinoma cells; furthermore, 
BN82685 was reported to retain its activity also when taken orally. The combination of 
BN82685 and paclitaxel (Taxol®) inhibits the proliferation of colon cancer cells [108], 
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suggesting that the synergism between CDC25 inhibitors and microtubule-targeting 
agents may be of therapeutic interest.  
 
Figure 5. Structures of some representative CDC25 inhibitors 
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Despite more than 40 patents have been reported for CDC25 inhibitors, spanning 
over 20 years of drug discovery efforts [109], no therapies targeting CDC25 
phosphatase are currently available in the clinic. A potent bis-quinone compound IRC-
083864138 under the name Debio0931 entered a phase II clinical trial in 2009, but no 
data are available yet because the trial was discontinued. Another CDC25 inhibitor, 
ARQ-501, entered phase I clinical trials in patients with advanced and chemotherapy-
unresponsive solid tumors, and is undergoing a phase II trial in patients with 
leiomyosarcoma and head and neck cancer, having completed an additional trial in 
combination with the nucleoside analog gemcitabine [110-111]. It is probable, however, 
that ARQ-501 is not directly a CDC25 inhibitor, but rather functions by some other 
mechanism. A novel approach to inhibit CDC25 phosphatase activity was recently 
reported by Cierpicki and co-workers. They identified a small molecule able to disrupt 
the protein-protein interactions between CDC25B and the Cdk2/CycA complex by 
fragment-based screening [112]. X-ray crystal structure revealed that this compound 
binds to a small but well-defined pocket, close to the hot spot region on CDC25B. 
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1.2 Melanoma 
Melanoma is the most dangerous type of skin cancer. It arises from melanocytes, 
specialized pigmented cells that are found predominantly in the skin. Melanocytes 
reside in the basal layer of the epidermis and in the hair follicles, and their homeostasis 
is regulated by epidermal keratinocytes [113]. In response to ultraviolet (UV) radiation, 
keratinocytes secrete factors that regulate melanocyte survival, differentiation, 
proliferation and motility, stimulating melanocytes to produce melanin and resulting in 
the tanning response. Thereby, melanocytes have a key role in protecting our skin from 
the damaging effects of UV radiation and in preventing skin cancer. Mutations in 
critical growth regulatory genes, the production of autocrine growth factors and the loss 
of adhesion receptors all contribute to disrupting the intracellular signalling in 
melanocytes, allowing them to escape their tight regulation by keratinocytes. 
Consequently, melanocytes can proliferate and spread, leading to formation of a naevus 
or common mole [113]. Melanocyte proliferation can be restricted to the epidermis 
(junctional naevus), the dermis (dermal naevus) or overlapping components of both 
(compound naevus) [113]. Naevi are generally benign but can progress to the radial-
growth-phase (RGP) melanoma, an intra-epidermal lesion that can involve some local 
microinvasion of the dermis. RGP cells can progress to the vertical-growth phase 
(VGP), a more dangerous stage in which the cells have metastatic potential, with 
nodules or nests of cells invading the dermis (Figure 6). Not all melanomas pass 
through each of these individual phases, as RGP or VGP can both develop directly from 
isolated melanocytes or naevi, and both can progress directly to metastatic malignant 
melanoma. Intermittent sun exposure (holiday time) and sunburns are significant risk 
factors for melanoma development [114].  
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1.2.1 Mechanisms and pathophysiology 
Transformation of melanocytes into melanoma requires a complex interplay of 
exogenous and endogenous events (Figure 7). Tremendous progress has been made in 
unravelling the genetic basis of melanoma. Melanomas carry the highest mutational 
load of all human tumours and harbour an overwhelming number of UV-signature 
mutations, such as C>T or G>T transitions, which are induced by UVB and UVA, 
respectively [114]. Current landscape genetic analyses provide compelling evidence for 
a direct mutagenic role of UVB and UVA light. However, UV-independent secondary 
cofactors are also involved in melanoma development. In fact, melanomas can develop 
in non-sun-exposed skin or in internal organs [114]. The mitogen-activated protein 
kinase (MAPK) cascade is currently the pathway that has the highest oncogenic and 
therapeutic relevance for melanoma; most mutations in this pathway are not directly 
attributable to UV damage [114]. The classic MAPK pathway in cutaneous melanoma 
transmits mitogenic signals from growth factors, such as hepatocyte growth factor 
(HGF), platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF), via 
Figure 6. Progression of melanocyte transformation [113].
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transmembrane receptor tyrosine kinases (RTKs) to the nucleus and transcriptional 
targets, such as cyclin D1. The MAPK signalling module comprises the small G protein 
Ras, which is attached to the inner leaflet of the plasma membrane, Raf, MEK and 
ERK, cytosolic protein kinases.  
 
 
Common mutations without typical UV signatures include BRAFV600E (detectable in 
~50% of all melanomas), NRASQ61L or NRASQ61R, KITV559A and GNA11Q209L 
mutations in GNAQ and GNA11 (which encode the guanine nucleotide-binding 
proteins Gαq and Gα11). Genetic evidence in melanoma also supports cooperation 
between cooperation between the MAPK pathway and the signalling pathway mediated 
by phosphatidylinositol 3‑kinase (PI3K), AKT, PTEN (phosphatidylinositol‑3,4,5-
trisphosphate 3‑phosphatase and dual-specificity protein phosphatase) and mammalian 
target of rapamycin (mTOR) as a cancer trigger [114]. PI3K can be activated by 
multiple signals, including RTKs and RAS, and subsequently phosphorylates 
phosphatidylinositols in the plasma membrane, which attract the RAC serine/threonine-
Figure 7. Signalling pathways in melanoma. A) Under normal conditions, mitogen-activated
protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)–Akt signalling permit
balanced control of basic cellular functions, including cell-cycle regulation, survival, motility
and metabolism. B) In melanoma, the depicted genetic alterations are frequently observed,
and lead to constitutive pathway activation (indicated by thick arrows) and loss of cellular
homeostasis. Adapted from [114]. 
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kinases Akt1, Akt2 and Akt3. The Akts are then activated by phosphorylation through 
3-phosphoinositide-dependent protein kinase 1 (PDK1) and mTOR complex 2 
(mTORC2). Activated Akts phosphorylate numerous downstream targets that regulate 
key cellular processes, such as growth, survival, motility and metabolism. The 
phosphatase PTEN antagonizes the activity of PI3K. The combination of mutated 
BRAF and focal deletions or mutations of PTEN is observed in most melanoma cell 
lines and also in up to 40% of human melanomas. It has been suggested that these 
mutations represent primary steps in the transformation of melanocytes that lead to 
oncogene-induced senescence. Senescence is a key cellular protection mechanism 
against cancer that halts aberrant cell proliferation. Cancer cells override senescence by 
inactivating key pathways such as those regulating p16INK4a/Rb (retinoblastoma protein) 
and p53. Full development of melanoma might require secondary or tertiary genetic 
aberrations to overcome senescence. For example, mutations in MAPK signaling and 
aberrations in cell-cycle control genes, such as CDKN2A (a locus that encodes the 
tumour suppressors p16INK4a and p14ARF), CDK4 and CCND1 (which encodes for cyclin 
D1) cooperate efficiently. Wild-type p16INK4A maintains cell-cycle control by inhibiting 
cyclin-dependent kinase 4 (CDK4) or CDK6-mediated phosphorylation and inactivation 
of retinoblastoma-associated protein (Rb), whereas functional p14ARF prevents 
ubiquitylation mediated by the E3 ubiquitin-protein ligase MDM2 and the subsequent 
degradation of cellular tumour antigen p53 (which is encoded by TP53). Thus, 
inactivating mutations in CDKN2A promote G1–S cell-cycle transition by loss of two 
important regulators of cellular homeostasis, Rb and p53. Furthermore, loss of function 
of other cell cycle inhibitors, such as p21CIP1 and p27KIP1 results in enhanced cyclin 
E/CDK2 activity that positively feeds back on itself and on CDK4/6 via CDC25. In 
particular, CDK2 is significantly and consistently overexpressed in metastatic 
melanomas (three to eight times more than in benign naevi), with the active and 
dephosphorylated form of this kinase being detected in metastatic melanoma tissues and 
melanoma cell lines [115]. CDC25A expression is much higher in the metastatic 
tumours and melanoma cell lines [115]. It was postulated that abnormal CDC25A 
expression or function in melanoma might be one of the initial steps in melanoma 
development [115].  
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For successful tumour development, melanoma cells modulate the tissue 
environment and, in particular, the immune response through a myriad of mechanisms. 
For example, melanomas co-opt immune-checkpoint pathways that normally mediate 
self-tolerance. By expression of programmed cell death protein 1 ligand 1 (PDL1; also 
known as B7-H1 and CD274) and PDL2, which are the ligands of the surface receptor 
programmed cell death protein 1 (PD1), melanoma cells limit T cell effector activity in 
the tumour tissue [114]. Alongside T cells, B cells and natural killer (NK) cells also 
express PD1 and are, therefore, also affected. By contrast, cytotoxic T lymphocyte 
protein 4 (CTLA4) is expressed exclusively on T cells, where it primarily dampens the 
amplitude of the initial T cell activation that occurs after antigen presentation by 
dendritic cells in the lymph nodes [114]. Additional mechanisms involved in 
immunosuppression are downregulation of tumour-associated antigens and MHC class I 
molecules, as well as immuno-editing and secretion of inhibitory factors such as 
transforming growth factor-β (TGF-β), interleukin-10 (IL-10) or nitric oxide [114]. 
 
1.2.2 Cell cycle alterations in melanoma: the role of CDC25 
Full development of melanoma might require secondary or tertiary genetic 
aberrations to overcome senescence. For example, mutations in MAPK signaling and 
aberrations in cell-cycle control genes, such as CDKN2A (a locus that encodes the 
tumour suppressors p16INK4a and p14ARF), CDK4 and CCND1 (which encodes for cyclin 
D1) cooperate efficiently (Figure 7) [114]. Wild-type p16INK4A maintains cell-cycle 
control by inhibiting cyclin-dependent kinase 4 (CDK4) or CDK6-mediated 
phosphorylation and inactivation of retinoblastoma-associated protein (Rb), whereas 
functional p14ARF prevents ubiquitylation mediated by the E3 ubiquitin-protein ligase 
MDM2 and the subsequent degradation of cellular tumour antigen p53 (which is 
encoded by TP53) [114]. Thus, inactivating mutations in CDKN2A promote G1–S cell-
cycle transition by loss of two important regulators of cellular homeostasis, Rb and p53. 
Phosphorylation of Rb leads to release of its associated protein, E2F transcriptional 
factor, which has the capability to activate the genes necessary for progression through 
the G1 phase. Loss of function of other cell cycle inhibitors, such as p21CIP1 and 
p27KIP1 results in enhanced cyclin E/CDK2 activity that positively feeds back on itself 
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and on CDK4/6 via CDC25 (Figure 8) [116]. In particular, CDK2 is significantly and 
consistently overexpressed in metastatic melanomas (three to eight times more than in 
benign naevi), with the active and dephosphorylated form of this kinase being detected 
in metastatic melanoma tissues and melanoma cell lines [115]. CDC25A expression is 
much higher in the metastatic tumours and melanoma cell lines [115]. It was postulated 
that abnormal CDC25A expression or function in melanoma might be one of the initial 
steps in melanoma development [115].  
 
Figure 8. Cell cycle regulation and melanoma. Branches of the cell cycle that are upregulated in 
melanoma appear in black; downregulated branches appear in dashed gray. Adapted from [115]. 
 
1.2.3 Therapeutic treatment of melanoma 
If melanoma is diagnosed early, it can be cured by surgical resection, and about 
80% of cases are dealt with in this way [113]. More advanced melanomas can be much 
harder to treat. Over several years, the standard treatment in clinical trials for metastatic 
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melanoma patients was the use of single-agent chemotherapy (dacarbazine, 
temozolomide or fotemustine) which offers a marginal clinical benefit [117]. Melanoma 
treatment options have evolved rapidly and include targeted therapeutics and immune 
checkpoint inhibitors.  
 
Targeted therapies 
After the discovery of the mutation in BRAF as a therapeutic target for those 
patients with metastatic melanoma, different BRAF inhibitor drugs have been tested in a 
clinical context with significant benefits in terms of increased response rate, increased 
progression-free survival (PFS) and increased overall survival (OS) in patients with the 
presence of a BRAF mutation. Within the classification of these drugs, two groups can 
be highlighted: non-selective BRAF inhibitors and selective BRAF inhibitors [117]. 
Non-selective BRAF inhibitors 
Sorafenib was the first BRAF inhibitor drug to undergo clinical testing in patients 
with metastatic melanoma. It has an activity directed toward multiple protein kinases as 
BRAF, CRAF, VEGF and PDGF in a non-selective manner. The clinical utility of 
sorafenib in melanoma has been proved to be very limited [117]. 
Selective BRAF inhibitors 
Vemurafenib (PLX4032 and its analog PLX4720) is an oral drug, which inhibits 
the growth of cells that have mutations in BRAFv600E by blocking the activation of 
MAPK kinase pathway with subsequent cell senescence in the G1 phase of the cycle 
and apoptosis. It was approved by the Food and Drug Administration (FDA) and the 
European Medicines Agency (EMA) for those patients with unresectable or metastatic 
melanoma BRAFV600E mutation carriers. Dabrafenib is another selective inhibitor of 
BRAFV600E and BRAFV600K mutations, which has shown comparable results to those, 
obtained with treatment with vemurafenib. Generally BRAF inhibitors are well tolerated 
with few potentially serious side effects. The most common side effects include skin 
changes, fatigue, diarrhea and nausea. The major side effect associated with BRAF 
inhibitors is the development of cutaneous squamous cell carcinomas and 
21 
 
keratoacanthomas. These lesions, which have a very fast growth, can be managed 
effectively by surgical removal without further evidence of recurrence [117]. 
Unfortunately, nearly all patients treated with BRAF inhibitors experience disease 
progression during the first 1 to 2 years of therapy. Therefore, elucidating mechanisms 
of acquired resistance has been a major clinical and research focus. Unlike many other 
cancers, resistance in BRAF-mutant melanoma is not the result of second site mutations 
in the target gene, BRAF. Instead, a diverse array of resistance mechanisms has been 
uncovered, largely involving acquired alterations in the MAPK pathway or parallel 
signaling networks. As such, attention has shifted to BRAF inhibitor–MEK inhibitor 
combinations targeting distinct MAPK pathway components. 
MEK Inhibitors 
Single-agent MEK inhibitors also have activity in BRAFV600 mutant melanoma. 
There are several MEK inhibitor drugs that have been tested in clinical trials for patients 
with metastatic or unresectable melanoma, among which there are selumetinib 
(AZD6244), PD-0325901, trametinib (GSK1120212), AS703026, cobimetinib (GDC-
0973/XL518) and MEK162 [117]. To date, no MEK inhibitor has demonstrated clinical 
effectiveness such as objectified with BRAF inhibitors. Only the MEK inhibitors 
trametinib, cobimetinib and MEK 162 have shown, in the clinical setting and in 
combination with BRAF inhibitors, increased activity in melanomas carriers of 
BRAFV600E mutations [117]. Although trametinib was approved by the FDA in 2013, it 
is rarely used as monotherapy because of presumably inferior efficacy compared with 
single-agent BRAF inhibitors. Newer MEK inhibitors are also being evaluated currently 
(cobimetinib, binimetinib) [118]. Combination of BRAF and MEK inhibitors has 
supplanted single-agent BRAF inhibitors as the preferred targeted therapy strategy for 
patients with BRAFV600 mutated melanoma. A phase II clinical trial compared 
dabrafenib and trametinib, combined at full monotherapy doses, with dabrafenib alone. 
Progression-free survival was significantly improved with combination therapy. On the 
basis of this study, dabrafenib and trametinib received FDA approval in early 2014.  
 
 
22 
 
Immunotherapies 
Immune therapy agents, starting with high-dose interleukin 2 (IL-2) and now with 
newer immune checkpoint inhibitors, are a cornerstone of melanoma therapeutics [118]. 
Another agent enhancing the immune system is interferon alpha (IFN-α), that showed a 
statistically significant improvement in both disease-free survival (DFS) and OS in 
adjuvant treatment of patients with high-risk cutaneous melanoma.  
Anti-CTLA4 
Ipilimumab is a monoclonal antibody to cytotoxic T lymphocyte antigen 4 
(CTLA4) and was the first agent to demonstrate an OS advantage in melanoma [118]. 
Ipilimumab blocks this negative regulator of T-cell activation and thus promotes 
previously inhibited immune responses. Development of tremelimumab is now ongoing 
in combination with other immune therapies. Ipilimumab received FDA approval in 
2011 and is an appropriate first-line treatment option for patients with or without BRAF 
mutations. The acute toxic effects of ipilimumab therapy are well characterized and 
quite distinct from those of both IL-2 and cytotoxic chemotherapy.  
Anti-PD-1/PD-L1 
Antibodies to PD-1 (nivolumab, pembrolizumab) or its ligand (PD-L1; 
MPDL3280A, MEDI4736) have also been recently tested in melanoma [118]. PD-L1 is 
frequently expressed by numerous malignant neoplasms as a mediator of immune 
escape. The interaction between PD-1 and PD-L1 induces T-cell anergy and ineffective 
antitumor responses in the so-called exhausted T cell. Inhibiting this interaction, 
therefore, restores T-cell function in the tumor microenvironment. At this time, the most 
effective target in this axis (PD-1 or PD-L1) is not clear. These agents, however, each 
have substantial clinical activity. Both pembrolizumab (MK-3475 a fully humanized 
IgG4 monoclonal antibody) and nivolumab (BMS-936558, a fully human IgG4 
monoclonal antibody) have received FDA approval for melanoma therapy following 
progression after ipilimumab and BRAF-targeted therapy for patients with BRAF V600 
mutations. 
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Combined Immune Therapy Strategies 
Because ipilimumab and anti-PD-1–directed therapies remove negative T-cell 
regulators at distinct phases of T-cell activation, combining these therapies was 
suggested as a synergistic approach [118]. Preclinical studies also demonstrated more 
effective antitumor activity in mouse models. The encouraging activity of these 
combination regimens has also led to a number of other anti-PD-1/PD-L1 combination 
approaches now being evaluated in early-phase trials, largely involving other immune 
modulators or targeted therapies. In contrast to BRAF and MEK inhibitors, no clearly 
defined biomarkers exist for predicting the outcome of immune therapies although there 
are several promising candidate approaches. Developing immune biomarkers will be a 
critical objective to improve clinical trial design and treatment decision making.  
 
Future strategies 
Restoration of disabled cell-cycle control emerges as a prime therapeutic goal for 
the majority of patients with melanoma [114]. Inhibitors of CDK4/6, MDM2, and 
ERK1/2 are particularly intriguing, especially in combination with MEK and/or BRAF 
inhibitors. Over the next years, the focus will be on understanding how resistance to 
targeted therapies develops and how to overcome potential crosstalk with other 
signalling pathways, leading to optimized patient selection and enhanced synergy of 
combination regimens. 
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1.3 Aim of the work 
Recently, Lavecchia et al. discovered a new series of CDC25 inhibitors by means 
of a structure-based virtual screening [38]. Among them, the most promising were  
1. Compound 11, 3-(4,5,6-trihydroxy-3-oxo-3H-xanthen-9-yl)-propanoic acid 
(NSC 119915), displaying irreversible inhibition kinetics with in vitro Ki values 
for CDC25A and CDC25B of 0.07 and 0.08 μM, respectively; 
2. Compound 19, 4-(2-carboxybenzoyl)phthalic acid (NSC 28620), displaying 
reversible inhibition kinetics with in vitro Ki values for CDC25A and CDC25B 
of 2.3 and 5.3 μM, respectively. 
Both compounds arrested cells at the G0/G1 and G2/M phases of the cell cycle, 
increased Cdk1 hyperphosphorylation in K562 leukemia cells, and significantly 
suppressed the growth of human MCF-7 breast, PC-3 prostate cancer lines as well as 
K562 leukemia cells, thus representing novel interesting leads. 
The aim of this thesis project was 
1. Identification of more active analogs of compound 11 by ligand-based 
chemoinformatic selection in order to expand our understanding of structure-
activity relationships (SARs) within the 6-xanthone class of CDC25 inhibitors 
and to examine their activity against melanoma cancer cell lines, as well as the 
mechanism of action involved; 
2. Optimization of compound 19 by structure-based drug design in order to 
improve its binding affinity and pharmacokinetic properties as well as to 
investigate its anti-melanoma effects. 
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2. Results and discussion 
 
2.1 Ligand-based chemoinformatic selection of new analogs of compound 11 
2.1.1 Similarity search using molecular fingerprints 
In order to identify novel structural analogs of lead compound NSC 119915 with 
increased CDC25 inhibitory potency, we applied different chemoinformatic approaches 
[119-120] against both the ZINC drug-like library and the NCI lead-like set. The 
general workflow is presented in Figure 9. The first five VS approaches employed 
molecular fingerprints, which are binary vectors encoding the presence, or absence, of 
substructural fragments within the molecule and have been successful in recognizing 
similar molecules in large databases [121].  
 
 
Figure 9. Flow chart of the multiple ligand-based chemoinformatic strategy implemented in this 
work.  
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We employed ECFP2, ECFP4, FCFP2, FCFP4, and FCFP6 to identify close active 
analogs to our lead NSC 119915, using the Tanimoto coefficient as similarity measure. 
Extended Connectivity Fingerprints (ECFPs) have been shown to have a number of 
strengths that make them useful for similarity searching. ECFPs are a fingerprint 
methodology explicitly designed to capture molecular features relevant to molecular 
activity. They can be quickly calculated, as they are not defined a priori [122]. 
Functional Class Fingerprints (FCFPs) are a related fingerprint to ECFPs but instead of 
using a specific atom identifier for the initial atom in the algorithm to generate the 
fingerprint, FCFPs use a more abstract pharmacophoric set of initial atom identifiers 
based on properties such as H-bond acceptor (HBA) and donor (HBD), negatively and 
positively ionizable, aromatic, and halogen [122]. To enhance the probability of finding 
50% of all possible actives, we used the threshold values suggested by Muchmore et al. 
[123]. The entire process was automated in a custom protocol using Pipeline Pilot 9.2 
(Figure 10). So, a Tanimoto threshold of 0.52 for ECFP2 allowed the selection of 13 
compounds, whereas a Tanimoto threshold of 0.43 for ECFP4 gave 12 compounds. For 
FCFP2, a Tanimoto threshold of 0.75 provided 16 compounds; for FCFP4, a Tanimoto 
threshold of 0.60 gave 5 compounds; and for FCFP6, a Tanimoto coefficient of 0.45 
highlighted 8 compounds. Thus, the combination of these five FP methods would 
hopefully maximize the chances of identifying compounds that were sufficiently similar 
to our lead compound to display inhibition of CDC25 phosphatases.  
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Figure 10. The protocol employed for similarity search by molecular fingerprints. 
 
2.1.2 Substructure search 
The sixth method utilized was the substructure search, using the core structure of 
NSC 119915. By definition, a substructure search identifies molecules that contain a 
defined molecular fragment, that is, a certain substructure. Of course, such a search will 
not lead to new scaffolds, but will allow the finding of close analogs and possible 
variations in the decoration of known molecule classes. A simple substructure searching 
via SMILES Arbitrary Target Specification (SMARTS) pattern implemented in 
Schrödinger Canvas 1.9 was used to filter both ZINC drug-like and NCI lead-like 
collections, using as query the following SMILES notations: [O = 
c3ccc2cc1ccccc1oc2c3], [O = c3ccc2cc1ccccc1[nH]c2c3] and [O = 
c3ccc2cc1ccccc1sc2c3]. The substructure search identified 137 scaffold isosteres of our 
lead core structure. The results of the six VS techniques were combined, and a 
significant number of identical compounds were removed; this overall strategy led to a 
final total of 126 unique compounds that were predicted by one or more methods to be 
similar in some way to our active compound. Then, we selected the top-ranked 25 
compounds that were purchased or requested from the NCI Developmental Therapeutics 
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Program (DTP) (Table 1). Our decision to select the top-ranked compounds was to 
ensure testing of any highly similar (and therefore likely to be active) compound. 
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Table 1. Compounds identified by multiple ligand-based chemoinformatic protocol. 
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2.1.3 Biological evaluation 
The inhibitory activity of the twenty-five structures identified from the multiple 
ligand-based chemoinformatic approach was evaluated by a fluorimetric assay. The 
residual phosphatase activity of a recombinant form of CDC25B was measured in the 
presence of two different concentrations of these compounds (Table 2). Eight 
compounds (2, 10, 12–14, and 16–18) were excluded from the analysis, because 
endowed with a strong fluorescent signal. Compounds 5-9, 21, 24, and 25 exerted a 
concentration-dependent inhibition of the CDC25B phosphatase activity, with a 
percentage of inhibition comparable to that exhibited by the lead compound NSC 
119915. The rest of the compounds caused a measurable inhibition only at the highest 
concentration. So, only compound 3 was included in the following analysis.  
Table 2. Residual phosphatase activity of CDC25B in the presence of NSC 119915 or its 6-
xanthone analogs. 
 
Compound 
CDC25B residual activity (%) in the 
presence of [inhibitor] 
0.2 µM                         1µM 
1 
3 
4 
5 
6 
7 
8 
9 
11 
15 
19 
20 
21 
22 
23 
24 
25 
NSC 119915 
76 
85 
90 
12 
14 
44 
10 
9 
89 
79 
86 
91 
13 
80 
80 
22 
24 
38 
9 
62 
28 
2 
2 
1 
1 
0 
44 
18 
70 
24 
1 
0 
14 
3 
1 
2 
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Kinetic analyses revealed that these nine compounds inhibited the three different 
CDC25 proteins in a noncompetitive manner with Ki values comparable to those of the 
lead compound NSC 119915 (Table 3). The Ki towards CDC25A ranged between 0.01 
and 0.80 μM, and the corresponding intervals for CDC25B and CDC25C were 0.12–2.4 
μM and 0.30–4.4 μM, respectively.  
Table 3. Ki values of NSC 119915 or its 6-xanthone analogs towards CDC25-A, -B and –C 
phosphatases. 
Compound Ki 
 CDC25A CDC25B CDC25C 
3 0.28± 0.09 2.4±0.39 4.4±0.62 
5 0.38±0.12 0.12±0.05 0.39±0.15 
6 0.10±0.03 1.1±0.37 1.0±0.41 
7 0.65±0.04 0.78±0.03 3.1±0.22 
8 0.17±0.07 0.19±0.08 0.30±0.12 
9 0.80±0.31 0.44±0.2 1.5±0.48 
21 0.14±0.06 0.14±0.05 0.63±0.14 
24 0.01±0.005 0.3±0.08 0.40±0.11 
25 0.40±0.15 1.1±0.4 0.96±0.38 
NSC 119915 0.34±0.12 0.10±0.04 0.24±0.13 
 
Concerning the mechanism of inhibition, the kinetic measurements showed that the 
tested compounds behaved similarly to the lead compound NSC 119915 [38], as 
noncompetitive inhibitors.  
As CDC25 phosphatases, in combination with other cell cycle regulators, have been 
proved to be of determinant significance for melanoma growth and/or transformation 
[115,124], we evaluated the effects of NSC 119915 and its close analogs on the growth 
rate of two melanoma cell lines, A2058 and SAN (Figure 11). Although analogs 6 and 
24, and NSC 119915 in some experimental conditions, caused a significant reduction of 
the cell growth rate in SAN cells, compound 7 [2-(6-hydroxy-3-oxo-3H-xanthen-9- 
yl)cyclohexanecarboxylic acid] resulted as the only common inhibitor of the cell growth 
rate of both A2058 and SAN melanoma cells. The failure of compounds 3, 5, 8, 9, 21 
and 25 to inhibit cell proliferation despite their potent inhibition of all three CDC25 
phosphatases could be due to poor permeability into cells, chemical instability, 
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unfavorable compartmentalization, active metabolism into inactive compounds, 
presence of unidentified binding proteins, or a combination of these factors.  
 
 
Thus, 7 was selected as the most promising compound for further investigation of its 
anti-melanoma effects. The minimum concentration of inhibitor that caused an evident 
cytotoxic activity was 100 μM, as demonstrated for compound 7. Therefore, this 
concentration was almost thoroughly used in the following experiments.   
As CDC25 phosphatases are key cell cycle regulators, the effect of 7 on cell cycle 
progression was investigated in detail. To this aim, asynchronously growing A2058 and 
SAN cells were treated at different times with 100 μM compound 7, and then cell cycle 
analysis was cytofluorimetrically monitored after propidium iodide (PI) incorporation. 
A significant reduction of the G0/G1 phase and an increase of the G2/M phase occurred 
in both melanoma cell lines after 16-h treatment and continued up to 24-h (Figure 12). 
The effect of 7 on cell growth and cycle progression could suggest the beginning of a 
cell death program, a hypothesis investigated through various methodological 
approaches.  
Figure 11. Effect of NSC 119915 and its close analogs on cell growth rate of
melanoma cell lines A) A2058  and B) SAN.  
33 
 
 
Figure 12. Effect of compound 7 on the distribution of cell cycle phases of A2058 cells after A) 
16 h or B) 24 h treatment. Vehicle alone, open bars; compound 7, black bars. 
 
We evaluated if the treatment of A2058 cells with compound 7 affected the protein 
levels of the three CDC25 isoforms. Compound 7 provoked an early reduction of the 
CDC25A protein levels up to 4 h, compared to untreated cells (Figure 13). This 
reduction disappeared under prolonged incubation times. Furthermore, a progressive 
and significant reduction of CDC25C protein levels was also observed. These overall 
results suggest that the modulation of the CDC25 protein levels induced by 7, in 
particular of the -A and more evidently of the -C form, could be related to the arrest of 
melanoma cells in G2/M observed in the presence of this inhibitor.  
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Figure 13. Effect of compound 7 on CDC25A, B and C protein levels.  
 
PI incorporation followed by flow cytometric analysis was used to detect the effect of 7 
on the number of nuclei with a sub-diploid content, a typical hallmark of apoptosis. A 
time-dependent increase of apoptosis was evident in both A2058 and SAN cells and in 
particular, the effect of 7 on cell death program was already evident after 24-h treatment 
(Figure 14). In A2058 cells the increase of apoptosis became significant at 48 h, and 
continued at least up to 72-h incubation (Figure 14A). In SAN cells a similar behaviour 
was observed and the increase of apoptosis was significant even at 24-h treatment 
(Figure 14B). To further investigate on the capacity of 7 to induce apoptosis, the 
enzymatic activity of caspase-3, the final effector of apoptotic program, was monitored. 
Indeed, this inhibitor provoked a significant increase of the enzymatic activity of 
caspase-3 in both A2058 (Figure 14C) and SAN cells (Figure 14D). To confirm that the 
pro-apoptotic effect of 7 was caspase-mediated, the 48-h treatment of A2058 and SAN 
cells with compound 7 was also carried out in the presence of an irreversible pan-
caspase inhibitor, such as Z-VAD-FMK. The level of apoptosis caused by 7 was 
significantly decreased in the presence of this inhibitor in both A2058 and SAN cells, 
thus demonstrating that the pro-apoptotic effect of 7 was mainly caspase-dependent. 
Taken together, all these data support the hypothesis that cell cycle arrest in G2/M 
phase caused by 7 could evolve in an apoptotic process. It is known that quinonoid 
35 
 
structures, as those of the most active CDC25 inhibitors, are good substrates for the 
beginning of a redox cycle, and that an increased ROS level may cause severe damages 
to the CDC25 structure [104,125-126]. Indeed, compound 7 increased the intracellular 
ROS levels in both A2058 (Figure 15) and SAN cell lines. The oxidant effect of 7 was 
also evaluated after cell pre-treatment with the antioxidant N-acetyl-cysteine (NAC).  
 
 
Figure 14. Effect of compound 7 on the apoptosis of A2058 (panels A and C) and SAN cells 
(panels B and D).  
 
Pre-incubation of A2058 and SAN cells with an anti-oxidant molecule prevented the 
apoptotic process; indeed, the apoptosis was in a great part reverted by the cellular pre-
treatment with NAC. Taken together, all these findings suggest that 7 altered the 
intracellular redox state of melanoma cells, thus mediating the observed cytotoxicity.  
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Figure 15. A) Time-dependent measurement of ROS production. B) Effect of the antioxidant 
NAC on ROS production.  
 
Mitochondria represent the primary source of ROS, as well as the target of ROS action, 
and therefore, compound 7 could affect their functionality in melanoma cells. A 
decrease of the fluorescent signal, corresponding to a reduction of the mitochondrial 
membrane potential, was already evident after 24-h treatment of A2058 cells with 7 and 
then continued at least up to 72 h (Figure 16A). Proteins belonging to the B-cell 
lymphoma-2 (Bcl-2) family are involved in the modulation of the mitochondrial 
functionality [127-128]. Therefore, we have evaluated the levels of the anti-apoptotic 
protein Bcl-2, as well as that of the pro-apoptotic Bcl-2-associated X protein (Bax), 
after incubation of A2058 cells with 7 (Figure 16B). We observed a clear reduction of 
the Bcl-2 level and an increase of Bax level. Moreover, the densitometric analysis also 
revealed a significant reduction of the Bcl-2/Bax ratio after 8 and 16 h of incubation 
with 7, a useful index to evaluate apoptosis (Figure 16C). To further investigate the 
occurrence of a mitochondrial-mediated apoptosis induced by 7, the caspase-9 activity 
was assayed. A clear increase of caspase-9 activity was measured in A2058 cells after 
24-h incubation with 7 (Figure 16D). The observed increase of ROS levels, as well as 
the decrease of the crucial parameter for controlling life and death of a cell, i.e. the Bcl-
2/Bax ratio, are clear markers of an involvement of the mitochondrion in the apoptotic 
program triggered by 7 in melanoma cells. 
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Figure 16. Effect of compound 7 on some apoptotic mitochondrial markers in A2058 cells. A) 
Measurement of the mitochondrial membrane depolarization. B) Evaluation of Bcl-2 and Bax 
protein levels. C) Densitometric analysis of the Bcl-2 and Bax protein levels, and Bcl-2/Bax 
ratio. D) Determination of the caspase-9 enzymatic activity.  
  
The molecular mechanisms that regulate the cytotoxic potential of 7 in melanoma cells 
were further investigated through the evaluation of the activation state of protein kinase 
B (pAkt), one of the key proteins involved in the control and regulation of cell survival 
[129-130].    Compound 7 provoked an early reduction of the protein level of pAkt with 
respect to total Akt in A2058 cells, which was already evident after 2-h and remained 
detectable until 4-h incubation (Figure 17A). Interestingly, it has been demonstrated that 
CDC25B mediates the activation of Akt, probably through a dephosphorylation 
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mechanism of specific protein kinases [67,131]. We suggest that the early reduction of 
pAkt levels could be related to a concomitant impairment of CDC25 functions. It is 
known that Akt regulates the process of cell survival by phosphorylating different 
substrates, directly or indirectly involved in the apoptotic program [132]. One of these 
targets is p53, a protein with a tumor-suppressor activity that regulates the cell cycle, as 
well as the expression of several genes involved in the apoptosis [132]. In particular, 
Akt negatively regulates the apoptosis, by enhancing the degradation of p53 via its 
phosphorylation, as well as by promoting the nuclear localization and binding of this 
factor to human murine double-minute 2 (MDM2) protein, a negative regulator of p53 
[132]; therefore, we tested if the CDC25 inhibitor 7 affected the protein levels of p53. 
We observed an increase of p53 protein level in A2058 cells treated with compound 7, 
already evident after 8-h, that became significant after 16-h treatment (Figure 17B).  
 
 
Figure 17. Effect of compound 7 on pAkt and p53 protein levels. A) Evaluation of pAkt protein 
levels. B) Evaluation of p53 protein levels.  
 
We can suggest that the modulation of p53 protein levels represents one of the 
molecular events linked to the early decrease of pAkt caused by 7.  
Chemoresistance represents a typical hallmark of advanced melanomas. It has 
been reported that the aggressive nature of melanoma is related to an accumulation of 
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mutations in several key proliferation- regulating mechanisms, as well as in apoptosis-
controlling pathways [113]. Defects in Akt expression occur in a significant proportion 
of malignant melanomas [133]. Under this concern, the early reduction of the pAkt 
protein levels caused by 7 was very interesting, because it has been demonstrated that 
CDC25B mediates the activation of Akt, probably through a dephosphorylation 
mechanism of specific protein kinases [67,131]. A key molecule involved in the 
regulation of cell cycle and apoptosis pathway is p53. Frequently, in melanoma this 
protein is not mutated, but its impaired functions depend on high levels of the 
phosphorylated form of MDM2, a typical inhibitor of p53 [134]. The time-dependent 
decrease of the basal level of p53 observed in both melanoma cells, and its higher level 
measured in treated cells mainly after a late incubation with 7, suggest that this 
compound could affect the p53 protein stability. Indeed, higher levels of p53 in treated 
compared to untreated cells could be ascribable to a reduced activation of Akt, because 
this protein is responsible for the MDM2 phosphorylation [135-136]. On the other hand, 
it is likely that the reduced activation of Akt modulates the functions of other 
downstream proteins; under this concern, one possible candidate seems to be Bax, 
because of the increased levels of this pro-apoptotic factor observed upon treatment of 
A2058 with 7. In conclusion, we suggest that the early reduction of pAkt levels could be 
related to a concomitant impairment of CDC25 functions. In turn, the reduced activation 
of Akt could cause the deregulation of other downstream pathways leading to an 
increase of ROS level and later on of p53 levels. 
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2.2 Lead optimization of compound 19 
2.2.1 Structure-based drug design strategy 
Optimization of compound 19 began with the analysis of its binding mode into the 
CDC25B catalytic domain, predicted by docking experiments [38]. As depicted in 
Figure 18, the carboxylate group of the benzoyl moiety binds deep in the active site 
pocket of CDC25B, making a salt-bridge with the R479 guanidinium group and a H-
bond with the catalytic backbone NHs of R479 and E478. This moiety approximates the 
binding mode of the sulfate ion bound to the catalytic site of the CDC25B crystal 
structure. The two carboxylate groups of the phthalic moiety (positions 1 and 2) bind in 
the “swimming pool” and form salt-bridges with both R482 and R544 side chains. 
Furthermore, the carbonyl group of the inhibitor accepts a H-bond from the Y428 OH 
group.  
 
Figure 18. Structure-based optimization of compound 19. A) Predicted binding mode of 
compound 19 (yellow sticks) within CDC25 catalytic domain (blue marine surface). Protein 
residues are highlighted as white sticks. Key H-bonding interactions are shown as dotted lines. 
B) Schematic overview of the rationally designed compounds illustrated in Table 4. 
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Structural analysis identified potential areas where both lipophilic and polar 
groups could be incorporated to make improved contacts with the enzyme. On the basis 
of these premises, the phthalic system of 19 was replaced with a bulkier naphthalene 
moiety, strategically directed into the upper inner wall of the swimming pool that is 
composed by both hydrophobic (F543, L445, M483, W550, P444, and L545) and polar 
residues (Y428, R479, R482, E446, R544, T547, and S549). Then, the naphthalene 
system was decorated with hydroxyl, methoxy or amino groups at positions 1, 2 and 3 
in the attempt to establish potential H-bonds with Y428, R479, R482, E446, R544, 
T547, and S549 side chains, resulting in improved activity. The replacement of the 
carbonyl bridge with an amino group was also explored, to evaluate the H-bonding 
acceptor or donor capability at this position. Finally, in order to investigate the 
importance of the 2-carboxy function of the benzoyl moiety, 2- or 3-carboxy derivatives 
and their corresponding ethyl esters were synthesized (Table 4). 
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Table 4. Rationally designed compounds. 
 
Cpd R1 R2 R3 R4 R5 X 
1 H H H COOH H CO 
1a OCH3 H H COOH H CO 
1b H OCH3 H COOH H CO 
1c OH H H COOH H CO 
2 H H H COOC2H5 H CO 
3 H H H COOH H NH 
3a OCH3 H H COOH H NH 
3b H OCH3 H COOH H NH 
3c OH H H COOH H NH 
3d H OH H COOH H NH 
4 H H H COOC2H5 H NH 
4a OCH3 H H COOC2H5 H NH 
4b H OCH3 H COOC2H5 H NH 
5 H H H H COOH NH 
5a OCH3 H H H COOH NH 
5b H OCH3 H H COOH NH 
5c OH H H H COOH NH 
5d H OH H H COOH NH 
5e H NH2 H H COOH NH 
5f H H NH2 H COOH NH 
6 H H H H COOC2H5 NH 
6a OCH3 H H H COOC2H5 NH 
6b H OCH3 H H COOC2H5 NH 
7 H H H H H NH 
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2.2.2 Synthesis of rationally designed compounds  
The general synthetic strategy followed for the preparation of derivatives with a 
carbonylic group as linker between the two aromatic systems is outlined in Scheme 1 
and Scheme 2. Grignard’s reagent was prepared in situ starting from the commercially 
available 1-bromonaphthalene in the presence of magnesium turnings. The 
organomagnesium halide was added to a solution of phthalic anhydride in dry 
tetrahydrofuran to afford compound 1. The subsequent Fischer esterification of the 
carboxylic group in ethanol with sulfuric acid as catalyst provided the final ester 2. 
 
Scheme 1 
 
Otherwise, in order to obtain the same class of compounds described in Scheme 1 
having an hydroxyl group on the naphthalene ring, a second synthetic approach was 
developed. The key intermediate 10, which was synthesized following the four-step 
procedure depicted in Scheme 9, reacted with the appropriate substituted 
naphthaldeydes 8a,b and the acid-catalyzed deprotection of the carboxylic moiety lead 
to the desired lactones 11a,b in alkaline condition. The oxidation of these last with 
potassium permanganate and 25% aqueous solution of KOH in pyridine affords the 2-
(methoxy-1-naphthyl)benzoic acids 1a and 1b. Finally, the cleavage of the methyl ether 
of 1a with a 1M solution of boron tribromide in dichloromethane provides the final 
products 1c.  
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Scheme 2 
 
In parallel, the synthesis of another class of derivatives, bearing an amino group in 
replacement of the carbonylic one between the two aromatic system was carried out. 
The appropriate substituted aryl halide and aryl amine underwent a Buchwald palladium 
catalyzed amination reaction (compounds 4, 4a,b, 6, 6a,b,g,h and 7) using a mixture of 
palladium acetate (Pd(OAc)2) and racemic 2,2’-bis(diphenylphosphino)-1,1’-binaphthyl 
(BINAP) as catalysts, in the presence of Cs2CO3 as base. Although the yield of the aryl 
amination reaction was critically hindered by the electron deficiency of the amine, the 
combination of the more nucleophilic amine and more electrophilic aryl bromo was 
used (procedure a and b in Scheme 3). A basic hydrolysis of the ester group was then 
performed and this led to the formation of the corresponding acids 3, 3a,b, 5, 5a,b,g,h. 
The cleavage of methoxy protection was performed with a 1M solution of boron 
tribromide in dichloromethane to afford compounds 3c,d, 5c,d. The N-Boc protecting 
group was hydrolyzed with HCl (4M in 1,4-dioxane) to obtain compounds 5e,f. 
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Scheme 3 
 
The key intermediates 8a,b and 16a,b used in the previously reactions were 
synthesized as outlined in Scheme 4. The reduction of the nitro-group of the 
commercial available 1-nitronaphthalene required the use of organosilicon reagent 
(Et3SiH) in the presence of a catalytic amount of PdCl2 to afford compound 12. The 
subsequent halogenation with bromine in acetic acid provided intermediate 13 whose 
treatment with sodium nitrite led to the formation of the diazonium salt 14, which was 
isolated and characterized. The conversion of 14 into the 4-bromo-2-
hydroxynaphthalene 15 was accomplished with sodium borohydrid. 
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Scheme 4 
 
Intermediate 15 or of the commercial available 4-bromo-1-hydroxynaphthalene 
(Scheme 5) were subsequently protected as methyl ether in the presence of iodomethane 
provide the intermediates 16a,b. Finally, the exchange of the halogen atom with lithium 
by treatment with a solution of n-butillithium in dry THF at -78°C, followed by the 
formylation with N,N-dimethylformamide, led to the final products 8a,b. 
Scheme 5 
 
The synthesis of intermediate 17 was performed using the same reaction 
conditions applied for the synthesis of the intermediate 12, as shown in Scheme 6. 
Scheme 6 
 
As depicted in Scheme 7, the appropriate bromonaphthylamine was N-protected with 
di-tert-butyl dicarbonate to obtain compounds (18g,h). 
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Scheme 7 
 
The protection of the substituted benzoic acids was achieved in two different ways 
(Scheme 8). In the first strategy (a) the commercially available 2-bromobenzoic acid 
was condensed with 2-amino-2-methyl-1-propanol in order to obtain the intermediate 
19. This latter was reacted with thionyl chloride in diethyl ether to obtain the oxazoline 
9 which underwent a metal-halogen exchange in the presence of the organolithim 
species nBuLi to give compound 10. In the second strategy (b), the free carboxylic acid 
was protected as esters (20, 21) using the classical reaction conditions of Fischer 
esterification. 
Scheme 8 
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2.2.3 Inhibitory activities of rationally designed compounds toward CDC25B 
The inhibition properties exerted by the rationally designed compounds showed in 
Table 4 on the recombinant form of CDC25B were investigated, using a fluorimetric 
assay. In a preliminary screening aimed at assessing their inhibition power, the residual 
phosphatase activity of CDC25B was measured in the presence of two increasing 
concentrations of the various compounds. The data presented in Table 5 show that ten 
molecules (compounds 2, 3d, 4, 4a, 4b, 5f, 6, 6a, 6b, 7) cause a well measurable 
inhibition, thus acting as powerful inhibitors of CDC25B. Conversely, six molecules 
(compounds 1, 1a, 1c, 3, 3a and 5b) were judged essentially ineffective, because the 
residual phosphatase activity measured in the presence of the highest concentration 
tested, i.e. 100 µM, was higher than 70%. The remaining eight molecules (compounds 
1b, 3b, 3c, 5, 5a, 5c-e) showed an intermediate behaviour of weak inhibitors, being able 
to cause a significant inhibition only when added at the highest concentration.  
An insight on the properties of the powerful CDC25B inhibitors (compounds 2, 
3d, 4, 4a, 4b, 5f, 6, 6a, 6b, 7) was carried out through kinetic measurements of the 
corresponding Ki values, because this parameter better evaluates the inhibition power of 
these molecules; furthermore, the usage of the kinetic approach gives an information on 
the inhibition mechanism exerted by these compounds on CDC25B. The measured 
values of Ki reported in Table 5 range in the interval 2.8–20.1 µM, thus confirming that 
all these molecules act as powerful inhibitors of CDC25B; moreover, some of them (i.e. 
compounds 6 and 6a) seem to act as more powerful inhibitors compared to the lead 
compound 19. The mechanism of inhibition was evaluated through Lineweaver-Burk 
plots of CDC25B phosphatase activity performed in the absence or in the presence of 
fixed concentrations of each inhibitor. Preliminary studies revealed that the group of ten 
powerful inhibitors could be splitted in two subgroups on the basis of the observed 
effects on KM for the substrate OMFP and Vmax of reaction. In particular, two of them 
(compounds 3d and 5f) caused a reduction of the KM without altering the Vmax value, 
thus allowing their ranking as competive inhibitors of CDC25B. On the other hand, the 
remaining eight compounds (2, 4, 4a, 4b, 6, 6a, 6b and 7) caused a significant decrease 
of the Vmax and in most cases an alteration of the KM. Therefore, these inhibitors cannot 
be ranked as competitive inhibitors, as they probably act as noncompetitive or mixed 
inhibitors. Interestingly, a look on the structure of these powerful inhibitors indicated 
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that both compounds 3d and 5f possess a free carboxylic group at position R4 and R5, 
respectively; conversely, compounds 2, 4, 4a, 4b, 6, 6a, and 6b have the carboxylic 
group at R4 or R5 masked as ethyl ester, whereas the remaining inhibitor 7 represents 
the scaffold structure of the lead compound 19, without any carboxylic group. 
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Table 5. Residual phosphatase activity in the presence of Compound 19 or rationally designed 
compounds. 
Cpd CDC25B residual activity (%) in the 
presence of [inhibitor] 
Ki (μM) 
 1 μM 3 μM 100 μM  
1 - 96 110 - 
1a - 96 89 - 
1b - - - - 
1c - 65 71 - 
2 87 - 1 11.2 
3 95 - 78 - 
3a - 81 81 - 
3b 97  49 - 
3c - 92 67 - 
3d 83 - 5 20.1 
4 93 - 1 13.8 
4a - - - 5.7 
4b 99 - 2 7.3 
5 - - - - 
5a - 72 57 - 
5b 90 - 79 - 
5c 95 - 44 - 
5d 73 - 14 - 
5e - - - - 
5f - - - 7.4 
6 - - - 2.8 
6a - - - 3.4 
6b - - - 7.7 
7 - - - 15.5 
Cpd 19  82 13 5.3 
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2.2.4 Docking studies and SAR rationalization  
In order to rationalize the obtained biochemical data, docking studies were carried 
out for those compounds showing the lowest Ki values: compound 5f, the most active 
derivative of the series bearing the free carboxylic function, and compound 6, the most 
active derivative among the ethyl esters. Furthermore, to gain further insights into the 
nature of the inhibition exhibited by 5f and 6, we explored possible positions and 
orientations of the synthetic substrate 3-O-methylfluorescein phosphate (OMFP) with 
the catalytic domain of CDC25B. The phosphate group of OMFP was positioned to 
occupy the same location as the sulfate ion bound to the catalytic site of the crystal 
structure and the fluorescein moiety occupying the swimming pool. This binding mode 
is similar to that reported in previous studies [99,101]. As depicted in Figure 19A, the 
carboxylate group of 5f was bound deeply into the active site pocket of CDC25B, 
similar to the natural pTyr substrate, while the naphthalene group extended into the 
“swimming pool”. In particular, the carboxylate made a salt-bridge with the R479 
guanidinium group and engaged several H-bonds with the catalytic backbone NHs of 
E474, F475, S477 and E478. The naphthalene group formed a cation-π interaction with 
R544 side chain within the “swimming pool” with a distance between the cation center 
and the ring center of 4.2 Å. Superposition of the models for 5f and OMFP (Figure 19C) 
revealed a steric interference at the catalytic site of the enzyme, which could explain the 
competitive nature of 5f seen in the kinetic studies. It is noteworthy that the acid 
derivatives bearing -NH2 and -OH substituents on the naphthalene ring displayed better 
inhibitory activity, while the insertion of methoxy groups was detrimental for the 
activity. Additionally, derivatives bearing the naphthalene ring without substituents 
showed little or no inhibitory activity. It is well-known that the interaction between the 
cation and the ring π cloud is electrostatic in nature and can be greatly affected by the 
nature of the attached substituents due to inductive and resonance effects. We can 
hypothesize that the electron-donating groups such as -NH2 and -OH at position R2 of 
the naphthalene ring enhance the cation-π interaction through the resonance effect, 
which results in an increase of the π electron density cloud of the naphtalene ring. On 
the other hand, the presence of the methoxy group, which is electron-withdrawing via 
induction, but becomes overall electron-releasing when resonance effects come into 
play, weakens the cation-π interaction due to steric hindrance, when it is inserted at 
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position R2, or due to the dominant electron-withdrawing inductive effect, when this 
group is placed on R1. 
 
 
Figure 19. Proposed binding modes of A) 5f (magenta sticks) and B) 6 (green sticks) within 
CDC25B catalytic domain (blue marine surface). Comparisons of the predicted binding mode of 
OMFP substrate (salmon sticks) with 5f C) and 6 D), obtained independently. Protein residues 
are highlighted as white sticks. Key H-bonding interactions are shown as dotted lines. 
 
Curiously, when the ethyl ester derivative 6 was docked to CDC25B, a different binding 
mode was found. It bound deeply into the swimming pool with the carbonyl ester 
accepting an H-bond from the side chain of R544, while the amino group established a 
further H-bond with the CO backbone of S549 (Figure 19B). Moreover, 6 was engaged 
in several hydrophobic interactions with the residues on the C-terminal helix, in 
particular with W550. Superposition of the model for 6 and OMFP (Figure 19D) didn’t 
show significant overlap, consistent with the observed noncompetitive inhibition. A 
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very similar binding mode was observed also for the other ester derivatives 2, 4a, 4b, 6, 
6a, and 6b.  
 
2.2.5 Antiproliferative effects of compounds 2, 4, 4a, 4b, 6, 6a, 6b and 7 
We selected a first group of compounds possessing the carboxylic group in R4 or 
R5 masked by ethyl ester (2, 4, 4a, 4b, 6, 6a and 6b) and showing similar kinetic 
parameters. Indeed, the presence of an ester group makes these molecules more 
lipophilic, thus enhancing their cellular uptake. Furthermore, the analysis was extended 
to the lead compound 19 and its scaffold structure (compound 7). Hence, the effects of 
these molecules on the cell growth rate of A2058 melanoma cell line were investigated. 
A preliminary MTT assay was carried out after different times of treatment, in the 
presence of different concentrations of inhibitor (Figure 20). After 24-h, only compound 
6a caused an evident cytotoxicity at 50 µM, whereas at 100 µM also compounds 2 and 
7 were active. When the incubation time was prolonged to 48 or 72 h, both compounds 
2 and 6a were cytotoxic at 50 µM concentration and, at 100 µM concentration, 
cytotoxicity was extended also to compounds 6, 6b and 7. 
 
Figure 20. Effect of the rationally designed compounds and compound 19 and on cell growth 
rate of melanoma cells A2058. 
 
In order to check the minimum cytotoxic concentration of the more active compounds 
(compounds 2 and 6a), the MTT assay was repeated at different incubation times using 
lower concentrations (1.25, 2.5 or 5 µM) of these inhibitors. The data of Figure 21 
indicate that only compound 6a exerted a significant reduction of proliferation, being 
cytotoxic at 5 µM after 48-h, and even at 2.5 µM after 72-h incubation. Future 
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investigations will be mainly focused on compounds 2 and 6a because of their 
citotoxicity observed in a reasonable concentration range.  
 
 
Figure 21. Evaluation of the antiproliferative effects of compounds 19, 2 and 6a using different 
concentrations. 
 
In conclusion, the careful analysis of CDC25B catalytic domain in complex with 
the lead compound 19 offered precious insight for structural optimization, allowing to 
disclose a novel series of potent derivatives. The described SARs and the very useful 
synthetic approach constitute important guidelines for the design of further improved 
inhibitors. 
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2.3 Conclusions 
CDC25 phosphatases have a central role in the complex regulation of signalling 
pathways that are involved in cell stress responses, proliferation and death. Considered 
their biological importance, this enzyme family has been the target of several drug 
discovery efforts. This research project has been mainly addressed to the discovery of 
novel CDC25 inhibitors, starting from two promising lead compounds identified in a 
previous virtual screening campaign. By using a range of ligand- and structure-based 
computational methods we have identified two major classes of inhibitors. The first one 
is a series of 6-xanthone derivatives, structural analogs of the lead compound 11 (NSC 
119915), which was identified by a ligand-based chemoinformatic approach. Nine 
compounds (3, 5–9, 21, 24, and 25) were identified with Ki values for CDC25A, -B and 
-C ranging from 0.01 to 4.4 μM. One of these analogs, 7, showed a high 
antiproliferative effect on human melanoma cell lines, A2058 and SAN. Compound 7 
arrested melanoma cells in G2/M, causing a reduction of the protein levels of CDC25A 
and, more consistently, of CDC25C. Furthermore, an intrinsic apoptotic pathway was 
induced, which was mediated by ROS, because it was reverted in the presence of 
antioxidant N-acetyl-cysteine (NAC). Finally, 7 decreased the protein levels of 
phosphorylated Akt and increased those of p53, thus contributing to the regulation of 
chemosensitivity through the control of downstream Akt pathways in melanoma cells. 
On the other hand, a series of novel derivatives of the second lead compound 19 was 
rationally designed using a structure-based approach. Ten molecules (compounds 2, 3d, 
4, 4a, 4b, 5f, 6, 6a, 6b, 7) acted as powerful inhibitors of CDC25B, with Ki values 
towards CDC25B ranging between 2.8-20.1 µM, thus confirming the validity of the 
design strategy. Among them, compounds 3d and 5f, bearing a free carboxylic group, 
acted as competitive inhibitors of CDC25B, whereas compounds 2, 4, 4a, 4b, 6, 6a, 6b, 
bearing the carboxylic group at R4 or R5 masked as ethyl ester, acted as noncompetitive 
or mixed inhibitors. Compound 7, containing only the “scaffold structure”, also showed 
a noncompetitive or mixed inhibition profile. The distinct inhibition profiles of these 
inhibitors were also reflected in their different binding modes, as predicted by the 
docking experiments carried out for compounds 5f and 6. The effects of compounds 2, 
4, 4a, 4b, 6, 6a, 6b and 7 on the cell growth rate of A2058 melanoma cell line were also 
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investigated. Compounds 2 and 6a significantly reduced the proliferation of A2058 
cells, being cytotoxic at 5 µM and 2.5 µM, respectively, after 72-h incubation. 
Overall, our data indicate that the reduced viability of melanoma cells observed 
after treatment with both the reported classes of inhibitors is probably related to the 
inhibition potency exhibited by these molecules on the CDC25 phosphatase activity. 
Therefore, the deregulation of CDC25 in melanoma cells suggests that this crucial 
element of cell cycle could be considered as a possible oncotarget in vivo. It is known 
that the success of advanced anti-melanoma strategies, for example therapies based on 
the usage of BRAF inhibitors, that selectively inhibit the proliferation of melanoma 
cells harbouring the BRAFV600E mutation, is not definitive. In fact, the patients usually 
relapse because of acquired drug resistance, possibly due to the activation of others 
survival pathways. An alternative strategy could be represented by the combination of 
two different drugs, co-targeting independent survival pathways that are critical for 
development and maintenance of melanoma. Hence, the study of the effects of CDC25 
inhibitors in melanoma cells could be helpful for finding other molecular pathways, as 
possible targets for melanoma treatment.  
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3. Experimental section 
3.1 Computational chemistry 
3.1.1 Chemoinformatic methods  
All of the approaches below were performed in parallel against the full ZINC 
drug-like subset (~17.8 million drug-like compounds) and the NCI lead-like set. 
Database: lead-like selection and preparation  
The NCI Open Database (http://dtp.cancer.gov/) with 260.071 compounds was 
obtained from ZINC [137-138]. The compound database was processed with FILTER 
version 2.0.2 (OpenEye Scientific Software Inc., Santa Fe, USA, 
http://www.eyesopen.com/) to select a subset of lead-like compounds. We used the 
default parameters in the lead-like filter without further modifications. The resulting 
database, referred in this work as the NCI lead-like set, contained 65.375 compounds.  
Molecular fingerprints  
Five types of molecular FPs ECFP2, ECFP4, FCFP2, FCFP4, and FCFP6 [122]  
were calculated using Pipeline Pilot (Accelrys Inc., San Diego, USA, http://accelrys. 
com/products/pipeline-Pilot/). The similarity between the lead compound NSC 119915 
and our compound libraries was assessed using the Tanimoto coefficient. The Tanimoto 
coefficient (Tc) is given by eq. 1: 
Tc (A, B) = ௖௔ା௕ି௖ 
where a and b are the number of bits set in the fingerprints of molecules A and B, 
respectively, and c is the number of bits set in both fingerprints. The Tc ranges between 
0 and 1, with 0 corresponding to no fingerprint overlap and 1 to identical fingerprints. It 
should be noted that, identical fingerprints do not necessarily correspond to identical 
molecules (as fingerprints are only abstractions of molecular structures). Furthermore, 
as defined by the above formula, the Tc only takes into account bits set to 1 (i.e., 
features present in the molecule). Hence, the magnitude of the Tc value will be greatly 
influenced by the bit density in the underlying fingerprint, which on the other hand, 
increases with molecular size and complexity [139]. The calculation of Tc translates 
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structural similarity into numerical values and can be interpreted as the “percentage of 
structural features shared between two compounds”, yet it is debatable which Tc value 
corresponds to “significant similarity”. There is no generally applicable Tc threshold for 
the indication of structural similarity, which is dependent on the molecular fingerprint 
applied [140]. In this work, we applied threshold values of 0.52, 0.43, 0.75, 0.60, 0.45 
in combination with ECFP2, ECFP4, FCFP2, FCFP4, and FCFP6 fingerprints, 
respectively, because they give much higher confidence in correlating structural 
similarity [123]. 
Substructure search  
ZINC drug-like and NCI lead-like collections were exposed to substructure 2D 
searching using as query the following SMILES notations: [O = 
c3ccc2cc1ccccc1oc2c3], [O = c3ccc2cc1ccccc1[nH] c2c3] and [O = 
c3ccc2cc1ccccc1sc2c3]. Canvas version 1.9 (Schrödinger, LLC, New York, USA) was 
used in this process by using SMILES Arbitrary Target Specification (SMARTS) filter 
module to carry out substructure search. All structures retrieved from both molecular 
fingerprints and substructure search were combined and duplicates were removed, thus 
obtaining a single database of 126 unique compounds. Out of these compounds, we 
selected the top-ranked 25 compounds for CDC25 inhibitory assay. 
 
3.1.2 Molecular modeling  
Protein and ligand preparation 
Docking experiments were carried out employing the crystal structure of 1QB0 
[24]. All crystallographic water molecules and other chemical components were 
omitted, the right bond orders as well as charges and atom types were assigned, and 
hydrogen atoms were added to the crystal structure. Arg, Lys, Glu, and Asp residues 
were considered ionized, while His was considered as neutral. Then the protein was 
submitted to a series of restrained, partial minimizations using the OPLS-AA force field 
[141] within the “Protein Preparation” module of Schrödinger’s Maestro version 10.5 
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(Schrödinger, LLC, New York, NY, 2016). The initial structures of the inhibitors were 
created, modified and energy-minimized with Maestro. 
Docking  
Docking of 5f and 6 into the catalytic domain of CDC25B was performed with the 
Gold software, which uses a genetic algorithm (GA) for determining the docking modes 
of ligands and proteins. The coordinates of the cocrystallized sulfate were chosen as 
active-site origin. The active-site radius was set equal to 13 Å. The Goldscore-CS 
docking protocol was adopted in this study [142]. In this protocol, the poses obtained 
with the original GoldScore function are rescored and reranked with the GOLD 
implementation of the ChemScore function [142]. To perform thorough and unbiased 
search of the conformation space, each docking run was allowed to produce 200 poses 
without the option of early termination, using standard default settings. The top solution 
obtained after re-ranking of the poses with ChemScore was selected. 
 
3.2 Biology 
Materials and reagents  
Compounds retrieved by ligand-based chemoinformatic selection protocol were 
purchased from commercial vendors or kindly provided from the NCI/DTP. 
Compounds were dissolved in DMSO, and stock solutions at 10 mM concentration were 
prepared. Recombinant forms of the catalytic domains of CDC25A, -B and -C were 
obtained through the vectors pET28a-CDC25A-cd, pET28a-CDC25B-cd and pET28a-
CDC25C-cd, kindly provided by H. Bhattacharjee (Florida InternationalUniversity, 
Herbert Wertheim College of Medicine, Miami, Florida). Protein purification was 
obtained essentially as previously described [38]. The synthetic substrate for CDC25 
phosphatase activity, OMFP, was purchased from Sigma-Aldrich. Dulbecco’s modified 
Eagle’s medium (DMEM), Roswell Park Memorial Institute (RPMI) 1640 medium, 
fetal bovine serum (FBS), L-glutamine, penicillin G, streptomycin, and trypsin were 
purchased from Lonza (Milano, Italy). Propidium iodide (PI), dichlorofluorescein 
diacetate (DCFH-DA), Rhodamine 123 (R123), N-acetyl- L-cysteine (NAC) and 
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apocynin were purchased from Sigma-Aldrich. A protease inhibitor cocktail was 
obtained from Roche Diagnostics S.p.A. (Monza, Italy). Caspase-3 and caspase-9 
fluorimetric assay kits were purchased from BioVision (Milpitas, CA, USA). The pan-
caspase inhibitor Z-VAD-FMK was purchased from Selleckchem (USA). Rabbit 
monoclonal antibody against glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
was obtained from Cell Signaling (Boston, MA, USA); mouse monoclonal antibody 
against CDC25A, CDC25C, or Bcl-2, rabbit polyclonal antibody against CDC25B, 
pAkt (Ser473) or Bax, and each secondary antibody conjugated to horseradish 
peroxidase were obtained from Santa Cruz Biotechnology (Heidelberg, Germany). All 
other chemicals were of analytical grade and were purchased from Sigma-Aldrich. 
In vitro assays of CDC25 phosphatase activity  
The enzymatic activity of the catalytic domains of CDC25A, -B and -C were 
determined through a fluorimetric method, which monitored the dephosphorylation of 
the synthetic substrate OMFP, essentially as previously described [38]. In steady-state 
enzyme kinetic studies, the residual phosphatase activity of purified recombinant 
CDC25B was measured at 30°C in the presence of different concentrations of the 
various inhibitors, using a computer-assisted Cary Eclipse spectrofluorimeter (Varian) 
equipped with an electronic temperature controller. Excitation and emission 
wavelengths were set at 485 and 530 nm, respectively; both excitation and emission 
slits were set at 10 nm. The reaction mixture contained 10 nM CDC25B and different 
concentrations of the various inhibitors in 500 μL final volume of 20 mM Tris-HCl, pH 
7.8, 1 mM DTT. DMSO was used as vehicle control. The reaction started by the 
addition of 25 μM OMFP, and the formation of the fluorescent product o-
methylfluorescein was monitored continuously. The rate of OMFP hydrolysis was 
expressed as arbitrary units per min (a.u./min). The comparison of the rates determined 
in the absence and in the presence of the various inhibitors allowed the calculation of 
the residual phosphatase activity, expressed as a percentage. The Km for OMFP and the 
maximum rate of OMFP hydrolysis (ΔAU/minmax) were obtained from Lineweaver–
Burk plots, carried out in the absence or in the presence of different inhibitor 
concentrations. For the calculation of the inhibition constant (Ki), the equation used 
depended on the type of inhibition. In the reversible competitive inhibition, Ki was 
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averaged from the increase of Km for OMFP in the presence of the inhibitor, according 
to Km′ = Km{1 + ([I]/Ki)}, where Km′ represents the Km for OMFP measured in the 
presence of the concentration [I] of the inhibitor. In the irreversible inhibition, Ki was 
averaged from the decrease of ΔAU/minmax in the presence of the inhibitor, according to 
ΔAU/minmax′ = ΔAU/minmax/{1 + ([I]/Ki)}, where ΔAU/minmax′ represents the 
maximum rate of OMFP hydrolysis measured in the presence of the concentration [I] of 
the inhibitor. 
Cell culture  
The human melanoma cell line A2058, kindly provided by CEINGE (Naples, 
Italy), and SAN cells [143] were derived from lymph nodal metastases and grown in 
DMEM and RPMI 1640, respectively, supplemented with 10% FBS, 2 mM L-
glutamine, 100 IU/mL penicillin G, and 100 μg/mL streptomycin in humidified 
incubator at 37°C under 5% CO2 atmosphere. All cells were split and seeded every 
three days and used during the exponential phase of growth. Cell treatments were 
always carried after 24 h from plating.  
3-(4,5-Dimethylthiazole-2-yl)-2,5- biphenyltetrazolium bromide (MTT) assay  
The MTT assay was used to detect cell proliferation essentially as previously 
described [144]. Briefly, A2058 and SAN cells were plated in 96-well microtiter plates 
(100 μL/well) at 4000 and 6000 cells/well, respectively. After 24-h seeding, cells were 
treated with the selected compounds added at 25, 50 or 100 μM concentration, or with 
0.5% (v/v) DMSO as a vehicle control. After 24-h, 48-h or 72-h treatment, and upon the 
addition of 10 μL of MTT solution in the dark, the plate was incubated for 3 h at 37°C 
under CO2 atmosphere. After medium aspiration and solubilization of formazan 
crystals, absorbance was measured at 570 nm, using an ELISA plate reader (Bio- Rad, 
Milano, Italy). 
Cell cycle analysis and evaluation of apoptosis  
Cells were seeded into 6-well plates at 3 × 105 cells/ well for 24 h at 37°C; after 
the addition of 100 μM 7 or 0.5% DMSO as a vehicle control, the incubation of treated 
cells continued for 16 or 24 h. After each treatment, cells were harvested with trypsin, 
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centrifuged and the pellet was resuspended in phosphate-buffered saline (PBS). For cell 
cycle analysis, cells were fixed with 70% (v/v) cold ethanol and stored at –20°C for 1 h. 
Then, cells were washed with cold PBS, centrifuged and the pellets were resuspended in 
200 μL of a non-lysis solution containing 50 μg/mL PI. For the evaluation of apoptosis, 
cells were not fixed in ethanol and directly resuspended in 200 μL of a hypotonic lysis 
solution containing 50 μg/mL PI. After incubation at 4°C for 30 min, cells were 
analyzed with a FACScan flow cytometer (Becton Dickinson) for evaluating the 
distribution in cell cycle phases or the presence of nuclei with a DNA content lower 
than the diploid. 
Measurements of caspase-3 and caspase-9 activity  
To estimate caspase-3 and caspase-9 activity during the treatment with compound 
7, the respective enzymatic activities were measured by using caspase-3 and -9 
fluorimetric assay kits, according to the manufacturer’s protocol, essentially as 
previously described [145]. Briefly, cells were seeded into 75 cm2 plates (2 × 106 
cells/plate) for 24 h at 37°C and then treated with 100 μM 7 or 0.5% DMSO. At the end 
of each incubation, cells were collected, washed with PBS, and finally lysed at 4°C in 
the cell lysis buffer. Cell lysates were incubated with 50 μM DEVD-AFC or LEHD-
AFC substrates at 37°C for 2 h, to detect caspase-3 or caspase-9 activity, respectively, 
using a Cary Eclipse fluorescence spectrophotometer (Varian). Excitation and emission 
wavelengths were set at 400 nm and 505 nm, respectively; both excitation and emission 
slits were set at 10 nm. 
Measurement of intracellular ROS content  
The intracellular ROS level was monitored using the oxidation-sensitive 
fluorescence probe DCFH-DA. Cells were seeded into 6-well-plates (3 × 105 
cells/plate) for 24 h at 37°C and then treated at various times with 100 μM compound 7 
or 0.5% DMSO. DCFH-DA was added in the dark at 10 μM final concentration 30-min 
before the end of each incubation; then, cells were collected, washed in PBS, and finally 
resuspended in 500 μL PBS for fluorimetric analysis. Measurements were realized in a 
Cary Eclipse fluorescence spectrophotometer (Varian); excitation and emission 
wavelengths were set at 485 nm and 530 nm, respectively; both excitation and emission 
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slits were set at 10 nm. The effect of 7 on ROS production was also estimated after 
pretreatment of cells with 10 mM NAC for 1 h. 
Evaluation of mitochondrial membrane potential  
Cells were seeded into 6-well-plates (3 × 105 cells/well) for 24 h at 37°C, and 
then incubated at 37°C for 1 h in the presence of 5 μM R123, washed twice with PBS, 
and placed in medium containing 100 μM compound 7 or 0.5% DMSO. After various 
times from treatment, cells were harvested, washed and centrifuged for 10 min at 4°C. 
The cellular pellet was resuspended in 500 μL PBS. The fluorescence of cell-associated 
R123 was detected in the above-mentioned fluorescence spectrophotometer, using 
excitation and emission wavelengths of 490 and 520 nm, respectively; both excitation 
and emission slits were set at 10 nm. 
Western blotting  
A2058 cells were seeded into 6-well-plates (3 × 105 cells/plate) for 24 h at 37°C 
and then treated at different times with 100 μM compound 7 or 0.5% DMSO. After 
treatment, cells were harvested, washed with PBS and then lysed in ice-cold modified 
radio immunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl, pH 7.4, 150 mM 
NaCl, 1% Nonidet P-40, 0.25% sodium deoxycholate, 1 mM Na3VO4 and 1 mM NaF), 
supplemented with protease inhibitors and incubated for 30 min on ice. The supernatant 
obtained after centrifugation at 12,000 rpm for 30 min at 4°C constituted the total 
protein extract. The protein concentration was determined by the method of Bradford, 
using bovine serum albumin (BSA) as standard [146]. Equal amounts of total protein 
extracts were used for Western blot analysis. Briefly, protein samples were dissolved in 
SDS-reducing loading buffer, run on 12% SDS/PAGE and then transferred to 
Immobilon P membrane (Millipore). The filter was incubated with the specific primary 
antibody at 4°C overnight and then with the secondary antibody at room temperature for 
1 h. Membranes were then analysed by an enhanced chemiluminescence reaction, using 
Super Signal West Pico kit (Pierce) according to manufacturer’s instruction; signals 
were visualized by autoradiography. 
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Statistical analysis  
Data are reported as average and standard error. The statistical significance of 
differences among groups was evaluated using ANOVA, with the Bonferroni correction 
as post hoc test or the Student t test where appropriate. The significance was accepted at 
the level of p < 0.05. 
 
3.3 Chemistry 
Reagents and solvents were purchased from Sigma-Aldrich and used without 
further purification. Some reactions involving air-sensitive reagents were performed 
under nitrogen atmosphere and anhydrous solvents were used when necessary. The 
Biotage-initiator microwave synthesizer was used. Reactions were monitored by thin 
layer chromatography analysis on aluminium-backed Silica Gel 60 plates (70-230 mesh, 
Merck), using a ultraviolet fluorescent lamp at 254 nm and 365 nm. Visualization was 
aided by opportune staining reagents. Purification of intermediates and the final 
compounds was performed by flash chromatography using Geduran® Si 60 (40-63 µm, 
Merck). 1H- and 13C- NMR spectra were recorded at room temperature on a Variant 300 
MHz Oxford instrument using TMS as internal standard. CDCl3, CD3OD, acetone-d6 
and DMSO-d6 were used as deuterated solvents for all the spectra run. Chemical shift 
are expressed as δ (ppm). Multiplicity is reported as s (singlet), br s (broadened singlet), 
d (double), t (triplet), q (quartet), m (multiplet), dd (double of doublets), dt (doublet of 
triplets). The coupling constants (J-values) are given in Hertz (Hz). All spectroscopic 
data match the assigned structures. The melting points were determined on a Buchi 
Melting Point B540 instrument. 
 
General procedure for the synthesis of aminonaphtalene derivates (12, 17). 
To a solution of the suitable 1-nitronaphthalene (200 mg, 1.155 mmol) and 
triethylsilane (0.74 mL, 4.633 mmol) in ethanol (5 mL) a catalytic amount of palladium 
(II) chloride (10 mol %) was added under an N2 atmosphere [147]. The resulting 
mixture was kept under stirring and a change of color was observed. The solvent was 
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evaporated and then water was added and decanted. The aqueous phase was extracted 
with diethyl ether (3x2mL). The organic phase was firstly treated with HCl 3N (2mL) 
and then the collected acidic acqueous solution, which contained the hydrochloride salt 
of naphtylamina, was basified with NaOH 25% (2mL) and extracted with diethyl ether 
(6x2mL). The organic phase was dried over anhydrous sodium sulfate and the solvent 
was evaporated under reduced pressure. 
1-aminonaphtalene 12. Starting compound: 1-nitronaphtalene. Reaction time: 10 
minutes. Purple solid (melting point: 47-50°C), 74 % yield. Molecular formula: C10H9N. 
Molecular Weight: 143.19 g/mol. Rf = 0.47 (cyclohexane/ethyl acetate 7:3). Eluent for 
chromatography: cyclohexane/ethyl acetate from (8:2) to (7:3). 1H NMR (300 MHz, 
CDCl3) δ 7.80-8.00 (m, 2H, ArH), 7.40-7.60 (m, 4H, ArH), 6.82 (d, J = 6 Hz, 1H, ArH), 
4.10 (br s, 2H, NH2, exchangeable with D2O) ppm. 
1-methoxy-4-aminonaphtalene 17. Starting compound: 1-methoxy-4-nitronaphtalene. 
Reaction time: 60 minutes. Light tan solid (melting point: 38-40°C), 49 % yield. 
Molecular formula: C11H11NO. Molecular Weight: 173.21 g/mol. Rf = 0.43 
(cyclohexane/ethyl acetate 8:2). Compound 17 was used in the next reaction without 
any further purification. 1H NMR (300 MHz, CDCl3) δ 8.27-8.24 (m, 1H, ArH), 7.84-
7.81 (m, 1H, ArH), 7.52-7.49 (m, 2H, ArH), 6.74-6.66 (m, 2H, ArH), 3.95 (s, 3H, 
OCH3), 3.85 (br s, 2H, NH2, exchangeable with D2O) ppm. 
 
Synthesis of 1-amino-2,4-dibromonaphthalene 13.  
To a solution of compound 12 (250 mg, 1.745 mmol) in acetic acid (1 mL) was 
added a 0-5°C solution of Br2 (0.27 mL, 5.235 mmol) in acetic acid (2 mL) [148]. 
Another 1 mL of acetic acid was added and the mixture was warmed at 60°C for 15 
min, during which the color solution changes from purple to orange. Then the mixture 
was cooled with and the salt was filtered, washed with acetic acid, and suspended in an 
excess of 1M NaOH. The product was collected by filtration, washed with water and 
dried to give a purple solid. The crude residue was purified by flash chromatography 
(cyclohexane/ethyl acetate 9:1) to provide compound 13. Violet solid (melting point: 
114-116 °C), 86 % yield. Molecular formula: C10H7Br2N. Molecular Weight: 300.98 
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g/mol. Rf = 0.33 (cyclohexane/ethyl acetate 8:2). Compound 17 was used in the next 
reaction without any further purification. 1H NMR (300 MHz, CDCl3) δ 8.17 (dd, J1 = 
12 Hz, J2 = 3 Hz, ArH) 7.77-7.83 (m, 1H, ArH), 7.79 (s, 1H, ArH), 7.50-7.62 (m, 2H, 
ArH), 4.63 (br s, 2H, NH2, exchangeable with D2O). 
 
Synthesis of 1-diazo-4-bromo-2-naphthol 14.  
To a stirred solution of compound 13 (250 mg, 0.831 mmol) in acetic acid (4 mL) 
and propionic acid (0.67 mL) at 8-10°C was gradually added sodium nitrite (86 mg, 
1.246 mmol) [148]. After stirring for 10 min the yellow-brown solution was poured into 
6 mL of ice water and the resulting mixture was rapidly filtered to remove a black tar. 
The aqueous phase was extracted with dichloromethane (6x2 mL). The collected 
organic phase was dried over anhydrous sodium sulfate, filtered and the solvent was 
evaporated under reduced pressure to give compound 14. Yellow-orange solid (melting 
point: 118-125°C), 98 % yield. Molecular formula: C10H5BrN2O. Molecular Weight: 
249.06 g/mol. 1H NMR (300 MHz, CDCl3) δ 8.08 (d, J = 9 Hz, 1H, ArH), 7.58 (t, J = 9 
Hz, 1H, ArH), 7.37 (t, J = 9 Hz, 1H, ArH), 7.28 (d, J = 9 Hz, 1H, ArH), 7.18 (s, 1H, 
ArH) ppm. 
 
Synthesis of 4-bromo-2-naphthol 15.  
To a suspension of compound 14 (200 mg, 0.803 mmol) in ethanol (3.5 mL), 
NaBH4 (30.4 mg, 0.803 mmol) was added at 0-10°C [148]. The solution was stirred 
until gas evolution ceased and the mixture appeared darker. After evaporating ethanol, 
the remaining residue poured into water, basified with 10% NaOH and then extracted 
with dichloromethane (2x2 mL), in order to purify the reaction mixture from the 
unreacted materials and impurities. Then the collected alkaline acqueous solution, 
which contains the sodium salt of compound 15, was acidified with 3M HCl and 
extracted with ethyl acetate (2x2 mL). The organic layer was dried over anhydrous 
sodium sulfate and evaporatied under reduced pressure, to afford a crude brown solid. 
The residue was purified by flash chromatography (cyclohexane/ethyl acetate 9:1 - Rf = 
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0.18) to provide the intermediate 15. Brown solid (melting point: 118-119°C), 75 % 
yield. Molecular formula: C10H7BrO. Molecular Weight: 223.07 g/mol. 1H NMR (300 
MHz, CDCl3) δ 8.14 (d, J = 7.8 Hz, 1H, ArH), 7.67 (d, J1 = 6.9 Hz, J2 = 1.8 Hz, 1H, 
ArH), 7.41-7.50 (m, 3H, ArH), 7.14 (d, J = 1.8 Hz, 1H, ArH), 4.98 (s, 1H, OH, 
exchangeable with D2O) ppm. 
 
General procedure for the synthesis of 4-bromo-methoxynaphtalene derivates (16a,b).  
To a solution of the required bromonaphthol (150 mg, 0.672 mmol) in dry N,N-
dimethylformamide (1 mL) sodium hydride (60% dispersion in mineral oil, 29.6 mg, 
0.739 mmol) was added under N2. After the evolution of H2 ceased, iodomethane (0.17 
mL, 2.688 mmol) was added and then the reaction mixture stirred at room temperature 
for 3 hours. After the evaporation of N,N-dimethylformamide, the resultant residue was 
extracted with ethyl acetate (3x2 mL). The collected organic phase was dried over 
anhydrous sodium sulfate and the solvent was evaporated under reduced pressure to 
give the desired derivatives. The crude oils were purified by flash chromatography 
(cyclohexane/ethyl acetate 9:1) to provide compounds 16a and 16b. 
4-bromo-2-methoxynaphtalene 16a. Starting compound: 15. Brown oil, 97 % yield. 
Molecular formula: C11H9BrO. Molecular Weight: 237.09 g/mol. Rf = 0.66 
(cyclohexane/ethyl acetate 9:1). 1H NMR (300 MHz, CDCl3) δ 8.15 (d, J = 7.5 Hz, 1H, 
ArH), 7.72 (d, J = 7.5 Hz, 1H, ArH), 7.41-7.52 (m, 3H, ArH), 7.12 (d, J = 2.4 Hz, 1H, 
ArH), 3.91 (s, 3H, OCH3) ppm. 
4-bromo-1-methoxynaphtalene 16b. Starting compound: 4-bromo-1-naphthol. Brown 
oil, 98 % yield. Molecular formula: C11H9BrO. Molecular Weight: 237.09 g/mol. Rf = 
0.56 (cyclohexane/ethyl acetate 9:1). 1H NMR (300 MHz, CDCl3) δ 8.28 (d, J = 8.4 Hz, 
1H, ArH), 8.18 (d, J = 8.4 Hz, 1H, ArH), 7.50-7.67 (m, 3H, ArH), 6.67 (d, J = 8.4 Hz, 
1H, ArH), 3.98 (s, 3H, OCH3) ppm. 
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General procedure for the synthesis of methoxy-1-naphthledhyde derivates (8a,b).  
To a solution of the proper bromomethoxynaphthalene (100 mg, 0.422 mmol) in 
anhydrous THF (4 mL) cooled to -78°C under N2 was added nBuLi (2.7M in eptane, 
0.39 mL, 1.055 mmol) and stirred for 1 hour. Anhydrous N,N-dimethylformamide (0.20 
mL, 2.532 mmol) was added and the reaction stirred for a further 1 hour at -78 °C. The 
reaction was quenched by slowly addition of cold water (0.5 mL), in order to neutralize 
the unreacted nBuLi, and THF and DMF were evaporated. The residue was poured into 
3N HCl (3 mL) and extracted with diethyl ether (6x2 mL). The combined organic layer 
were washed firstly with water, then with a saturated sodium hydrogen carbonate 
solution and, finally, with a saturated sodium chloride solution. The organic phase was 
dried, filtered and concentrated. The crude oils were purified by flash chromatography 
(cyclohexane/ethyl acetate 9:1) to provide compounds 8a and 8b. 
3-methoxy-1-naphthaldehyde 8a. Starting compound: 16a. Yellow-brown oil, 56 % 
yield. Molecular formula: C12H10O2. Molecular Weight: 186.21 g/mol. Rf = 0.38 
(cyclohexane/ethyl acetate 9:1). 1H NMR (300 MHz, CDCl3) δ 10.36 (s, 1H, CHO), 
9.16-9.02 (m, 1H, ArH), 7.84-7.75 (m, 1H, ArH), 7.68-7.60 (m, 1H, ArH), 7.57-7.47 
(m, 2H, ArH), 7.38 (d, J = 2.5 Hz, 1H, ArH), 3.95 (s, 3H, OCH3) ppm. 
4-methoxy-1-naphthaldehyde 8b. Starting compound: 16b. Yellow-brown oil, 89 % 
yield. Molecular formula: C12H10O2. Molecular Weight: 186.21 g/mol. Rf = 0.25 
(cyclohexane/ethyl acetate 9:1). 1H NMR (300 MHz, CDCl3) δ 10.18 (s, 1H, CHO), 
9.30 (d, J = 8.6 Hz, 1H, ArH), 8.32 (d, J = 7.8 Hz, 1H, ArH), 7.88 (d, J = 8.0 Hz, 1H, 
ArH), 7.69 (t, J = 7 Hz, 1H, ArH), 7.56 (t, J = 8.3 Hz, 1H, ArH), 6.88 (d, J = 8.0 Hz, 
1H, ArH), 4.04 (s, 3H, OCH3) ppm. 
 
General procedure for formation of Boc-protected amines (18g,h). 
To a solution of the proper bromo-1-naphthalenamine (300 mg, 1.351 mmol) in 
ethanol (2.5 mL) di-tert-butyl dicarbonate (442.3 mg, 2.026 mmol) was added [149]. 
The resulting mixture was kept under stirring for 24 hours at 30°C. Then the solvent 
was evaporated under reduced pressure and the crude oil was purified by flash 
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chromatography eluting with cyclohexane/ethyl acetate (9:1) to afford compound 18g or 
18h. 
tert-butyl-4-bromonaphthylcarbamate 18g. Starting compound: 1-amino-4-
bromonaphthalene. Foam, 98 % yield. Molecular formula: C15H16BrNO2. Molecular 
Weight: 322.20 g/mol. Rf = 0.33 (cyclohexane/ethyl acetate 9:1). 1H NMR (300 MHz, 
CDCl3) δ 8.25 (d, J = 7.5 Hz, 1H, ArH), 7.86 (d, J = 8.1 Hz, 1H, ArH), 7.71-7.77 (m, 
2H, ArH), 7.51-7.62 (m, 2H, ArH), 6.89 (br s, 1H, NH, exchangeable with D2O), 1.56 
(s, 9H, CH3) ppm. 
tert-butyl-5-bromonaphthylcarbamate 18h. Starting compound: 1-amino-5-
bromonaphthalene. Light pink foam, 85 % yield. Molecular formula: C15H16BrNO2. 
Molecular Weight: 322.20 g/mol. Rf = 0.53 (cyclohexane/ethyl acetate 8:2). 1H NMR 
(300 MHz, CDCl3) δ 7.99 (d, J = 8.7 Hz, 1H, ArH), 7.79-7.87 (m, 2H, ArH), 7.73 (d, J 
= 7.5 Hz, 1H, ArH), 7.50 (t, J = 8.1 Hz, 1H, ArH), 7.28 (t, J = 8.1 Hz, 1H, ArH), 6.73 
(br s, 1H, NH, exchangeable with D2O), 1.49 (s, 9H, CH3) ppm. 
 
Synthesis of 4,4-dimethyl-2-(2-bromophenyl)oxazoline 9.  
Thionyl chloride (1.09 mL, 14.924 mmol) was added to 2-bromobenzoic acid 
(1000 mg, 4.975 mmol) under N2 and the mixture was refluxed for 6 hours. Then the 
excess of thionyl chloride was removed under vacuum. The ice-cold solution of the 
remaining acyl chloride in dry dichloromethane (2 mL) was added dropwise to a 
solution of 2-amino-2-methyl-1-propanol (886.9 mg, 9.950 mmol) in dichloromethane 
(2 mL) at 0°C. The mixture was stirred at room temperature for 2 hours. In order to 
purify the reaction mixture from the unreacted 2-amino-2-methyl-1-propanol, the 
organic phase was washed with 3N HCl (3x1 mL), dried over anhydrous sodium sulfate, 
filtered and the solvent was evaporated under reduced pressure. The crude 19 was used 
in the following reaction without further purification. White foam, 98 % yield. 
Molecular formula: C11H14BrNO2. Molecular weight: 272.14 g/mol. Rf = 0.67 
(dichloromethane/methanol 9:1). 1H NMR (300 MHz, CDCl3) δ 7.51 (dd, J1 = 8.1 Hz, 
J2 = 1.1 Hz, 1H, ArH), 7.43 (dd, J1 = 7.7 Hz, J2 = 1.8 Hz, 1H, ArH), 7.29 (dt, J1 = 8.1 
Hz, J2 =1.1 Hz, 1H, ArH), 7.20 (dt, J1 = 7.7 Hz, J2 = 1.8 Hz, 1H, ArH), 5.97 (br s, 1H, 
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exchangeable with D2O), 3.96 (br s, 1H, exchangeable with D2O), 3.63 (s, 2H, CH2), 
1.35 (s, 6H, CH3) ppm. 
In order to obtain the final compound 9, thionyl chloride (1.07 mL, 14.625 mmol) 
was added dropwise to benzamide 19 (1326.8 mg, 4.875 mmol). When the vigorous 
reaction had subsided, 6 mL of dry diethyl ether was added to the yellow solution. The 
excess of thionyl chloride was evaporated under reduce pressure to provide white 
crystals of the hydrochloride salt which was neutralized with cold 20% sodium 
hydroxide (2 mL) and extracted with diethyl ether (3x2 mL). The organic phase was 
dried over anhydrous sodium sulfate and the solvent was evaporated under reduced 
pressure. The crude brown oil was purified by flash chromatography eluting firstly with 
cyclohexane/ethyl acetate (98:2) and then with cyclohexane/ethyl acetate (9:1) to afford 
compound 9. Pale yellow oil, 79 % yield. Molecular formula: C11H12BrNO. Molecular 
weight: 254.12 g/mol. Rf = 0.15 (cyclohexane / ethyl acetate 9:1). 1H NMR (300 MHz, 
CDCl3) δ 7.62-7.54 (m, 2H, ArH), 7.18-7.31 (m, 2H, ArH), 4.08 (s, 2H, CH2), 1.35 (s, 
6H, CH3) ppm. 
 
General procedure for the synthesis of ethyl-bromobenzoate derivates (20, 21, 2).  
To a solution of the suitable bromobenzoic acid (500 mg, 2.487 mmol) in ethanol 
(1mL) a catalytic amount of concentrated sulfuric acid was added dropwise. The 
resulting mixture was kept under stirring at reflux overnight and, after cooling, the 
solvent was evaporated under reduced pressure. Ethyl acetate (3 mL) was added and the 
organic layer was firstly wash with a saturated solution of sodium bicarbonate (1x2 mL) 
and then with water (2x2 mL). The organic solvent was dried over anhydrous sodium 
sulfate and evaporated. Purification with flash chromatography (eluent: 
cyclohexane/ethyl acetate 9:1) was performed. 
Ethyl-2-bromobenzoate 20. Starting compound: 2-bromobenzoic acid. Pail brown oil, 
56 % yield. Molecular formula: C9H9BrO2. Molecular Weight: 229.07 g/mol. Rf = 0.63 
(cyclohexane/ethyl acetate 9:1). 1H NMR (300 MHz, CDCl3) δ 7.73 (dd, J1 = 7 Hz, J2 = 
2 Hz, 1H, ArH), 7.60 (dd, J1 = 8 Hz, J2 = 1.5 Hz, 1H, ArH), 7.28 (m, 2H, ArH), 4.36 (q, 
J = 7.2 Hz, 2H, CH2), 1.36 (t, J = 7.2 Hz, 3H, CH3) ppm. 
71 
 
Ethyl-3-bromobenzoate 21. Starting compound: 3-bromobenzoic acid. Pail brown oil, 
65 % yield. Molecular formula: C9H9BrO2. Molecular Weight: 229.07 g/mol. Rf = 0.72 
(cyclohexane/ethyl acetate 9:1). 1H NMR (300 MHz, CDCl3) δ 8.18 (t, J = 1.8 Hz, 1H, 
ArH), 7.97 (dt, J1 = 8.1 Hz, J2 = 1.2 Hz, 1H, ArH), 7.67 (ddd, J1 = 8.1 Hz, J2 = 1.8 Hz, 
J3 = 1.2 Hz, 1H, ArH), 7.30 (t, J1 = 8.1 Hz, 1H, ArH), 4.37 (q, J = 7.2 Hz, 2H, CH2), 
1.39 (t, J = 7.2 Hz, 3H, CH3) ppm. 
Ethyl-2-naphthoylbenzoate 2. Starting compounds: 1. Yellow oil, 60 % yield. Molecular 
formula: C20H16O3. Molecular Weight: 304.34 g/mol. Rf = 0.38 (cyclohexane/ethyl 
acetate 9:1). 1H NMR (300 MHz, CDCl3) δ 9.07 (d, J = 8.4 Hz, 1H, ArH), 7.99 (m, 2H, 
ArH), 7.90 (d, J = 8.4 Hz, 1H, ArH), 7.50-7.60 (m, 5H, ArH), 7.45 (d, J = 7.5 Hz, 1H, 
ArH), 7.36 (t, J = 8.4 Hz, 1H, ArH), 3.90 (q, J = 7.2 Hz, 2H, CH2), 0.91 (t, J = 7.2 Hz, 
3H, CH3) ppm. 
 
General procedure for the synthesis of synthesis of 3-(methoxy-1-naphthyl)phthalide 
derivatives (11a,b)  
To a solution of compound 9 (200 mg, 0.787 mmol) in dry diethyl ether (1 mL) at 
-78 °C was added dropwise 0.58 mL of a 2.7 M solution of nBuLi in heptane (1.574 
mmol), under N2 [150]. The solution was stirred at -78°C for 1 hour, then the suitable 
methoxy-1-naphthaldehyde 8a or 8b (146.5 mg, 0.787 mmol) was added and the 
reaction mixture was stirred at room temperature overnight. To quench the unreacted 
nBuLi, cold water (1 mL) was dropped in the reaction mixture and then the aqueous 
phase extracted with ethyl acetate (3x2 mL). The organic phase was dried over 
anhydrous sodium sulfate and the solvent was evaporated under reduced pressure. The 
obtained oil (284.3 mg) was dissolved in a solution of 3N HCl (1.5 mL), and the 
mixture was heated at reflux for 4.5 hours. After cooling, the solid was collected and 
washed with water, in order to be taken up in aqueous 10% NaOH (1.5 mL) and heated 
at reflux for 1 hour. The product was collected on acidification with 3N HCl (2 mL), 
extracted into ethyl acetate, washed with water and dried over sodium sulfate 
anhydrous. The solvent was evaporated under reduced pressure to give a crude solid 
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which was purified by flash chromatography eluting with cyclohexane/ethyl acetate 
(8:2). 
3-(3-methoxy-1-naphthoyl)phthalide 11a. Starting compounds: compound 8a and 9. 
Foam, 52 % yield. Molecular formula: C19H14O3. Molecular Weight: 290.31 g/mol. Rf = 
0.37 (cyclohexane/ethyl acetate 8:2). 1H NMR (300 MHz, CDCl3) δ 8.15 (d, J = 8 Hz, 
1H, ArH), 8.00 (d, J = 8 Hz, 1H, ArH), 7.81 (d, J = 7.7 Hz, 1H, ArH), 7.40-7.67 (m, 5H, 
ArH), 7.13-7.20 (m, 2H, ArH), 6.95 (d, J = 2.5 Hz, 1H, ArH), 3.86 (s, 3H, OCH3) ppm. 
3-(4-methoxy-1-naphthoyl)phthalide 11b. Starting compounds: compound 8b and 9. 
Oil, 21 % yield. Molecular formula: C19H14O3. Molecular Weight: 290.31 g/mol. Rf = 
0.41 (cyclohexane/ethyl acetate 8:2). 1H NMR (300 MHz, CDCl3) δ 8.29 (d, J = 8.1 Hz, 
1H, ArH), 8.09 (d, J = 8.4 Hz, 1H, ArH), 7.94 (d, J = 7.2 Hz, 1H, ArH), 7.46-7.62 (m, 
4H, ArH), 7.36 (d, J = 7.8 Hz, 1H, ArH), 7.06-7.09 (m, 2H, ArH), 6.63 (d, J = 8.1 Hz, 
1H, ArH), 3.91 (s, 3H, OCH3) ppm. 
 
Synthesis of 2-(1-naphthyl)benzoic acid 1.  
A mixture of 1-bromonaphthalene (200 mg, 0.966 mmol), magnesium turnings 
(47 mg, 1.931 mmol), and a catalytic amount of iodine in dry THF (2 mL) was refluxed 
under N2 until the formation of the Grignard reagent. Hence it was added dropwise, 
under N2, to a solution of phthalic anhydride (143.1 mg, 0.966 mmol) in dry THF (1.5 
mL) and the resulting mixture was heated under reflux for 48 hours. The reaction 
mixture was quenched with 0.5 mL of a saturated aqueous solution of ammonium 
chloride. The solvent was evaporated and then the aqueous layer was extracted with 
ethyl acetate (3x2 mL). In order to purify the reaction mixture from the unreacted 
starting material, the organic phase was firstly treated with saturated solution of sodium 
bicarbonate (1 mL) and then the collected alkaline aqueous layer, which contained the 
sodium salt of compound 1, was acidified by 3N HCl and extracted with ethyl acetate 
(3x2 mL). The organic phase was dried over anhydrous sodium sulfate, filtrated and the 
solvent was evaporated under reduced pressure. The crude oil was purified by flash 
chromatography eluting firstly with cyclohexane/ethyl acetate (8:2) and then with 
dichloromethane/methanol (95:5) to afford compound 1. Pale green oil, 73 % yield. 
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Molecular formula: C18H12O3. Molecular Weight: 276.29 g/mol. Rf = 0.28 
(dichloromethane/methanol 95:5). 1H NMR (300 MHz, CD3OD) δ 8.94 (d, J = 8.1 Hz, 
1H, ArH), 7.98 (d, J = 8.1 Hz, 1H, ArH), 7.82-7.94 (m, 2H, ArH), 7.30-7.62 (m, 7H, 
ArH) ppm. 
 
General procedure for the synthesis of 2-(methoxy-1-naphthyl)benzoic acids (1a,b).  
To a stirred mixture of the proper lactone 11a or 11b (50 mg, 0.172 mmol) in 25% 
KOH (1 mL) and pyridine (0.5 mL) powdered KMnO4 (43.5 mg, 0.275 mmol) was 
added, and the mixture was heated at reflux for 5 hours. The hot mixture was filtered 
and the residue was washed with water. Then the filtrate was extracted with diethyl 
ether (2x2 mL) to remove any unreacted lactone. The aqueous phase was acidified with 
3N HCl (2 mL), extracted with ethyl acetate (3x2 mL), washed with water and the 
organic layer was dried over sodium sulfate anhydrous. The organic solvent was 
evaporated under reduced pressure to give a crude oil which was purified by flash 
chromatography eluting firstly with cyclohexane/ethyl acetate (8:2) and then (1:9) to 
afford compound 1a or 1b. 
2-(3-methoxy-1-naphthoyl)benzoic acid 1a. Oil, 71 % yield. Molecular formula: 
C19H14O4. Molecular Weight: 306.31 g/mol. Rf = 0.31 (dichloromethane/methanol 
95:5). 1H NMR (300 MHz, CD3OD) δ 8.81 (d, J = 9 Hz, 1H, ArH), 7.89 (dd, J1 = 6 Hz, 
J2= 3 Hz, 1H, ArH), 7.80 (d, J = 9 Hz, 1H, ArH), 7.40-7.60 (m, 6H, ArH), 6.99 (d, J = 3 
Hz, 1H, ArH), 3.82 (s, 3H, OCH3) ppm. 
2-(4-methoxy-1-naphthoyl)benzoic acid 1b. Brown foam, 36 % yield. Molecular 
formula: C19H14O4. Molecular Weight: 306.31 g/mol. Rf = 0.20 
(dichloromethane/methanol 95:5). 1H NMR (300 MHz, CD3OD) δ 9.12 (d, J = 8.4 Hz, 
1H, ArH), 8.28 (d, J = 8.7 Hz, 1H, ArH), 7.87-7.90 (m, 1H, ArH), 7.62 (dt, J1 = 7.2 Hz, 
J2 = 1.5 Hz, 1H, ArH), 7.45-7.54 (m, 4H, ArH), 7.36-7.39 (m, 1H, ArH), 6.76 (d, J = 
8.1 Hz, 1H, ArH), 4.02 (s, 3H, OCH3) ppm. 
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General procedure for the synthesis of ethyl-(naphthylamino)benzoates (4, 4a,b, 6, 
6a,b,g,h, 7).  
Procedure a. A dried flask was purged with argon, charged with (±)-BINAP (3% 
mmol) and toluene (2.7 mL) was added [151]. The mixture was heated to 80 °C under 
stirring until the BINAP was dissolved. The solution was cooled to room temperature, 
and Pd(OAc)2 (2% mmol) was added. The mixture was stirred at room temperature for 
1 minute, then a solution of the proper 1-bromonaphthalene (1.0 mmol) and the 
corresponding ethyl aminobenzoate (0.8 mmol) in toluene (0.5 mL) was added. Finally, 
Cs2CO3 (1.14 mmol) and other toluene (2 mL) were added to the reaction mixture. The 
solution was heated at 80 °C under stirring, then was cooled to room temperature, 
diluted with diethyl ether, filtered, and concentrated. The obtained crude product was 
purified by column chromatography to provide the desired adduct. 
Procedure b. A dried flask was purged with argon, charged with (±)-BINAP (3% 
mmol) and toluene (2.7 mL) was added. The mixture was heated to 80 °C under stirring 
until the BINAP was dissolved. The solution was cooled to room temperature, and 
Pd(OAc)2 (2% mmol) was added. After stirring of the mixture at room temperature for 1 
minute, a solution of proper ethyl bromobenzoate (1.0 mmol) with appropriate 
naphthylamine (0.8 mmol) in toluene (0.5 mL) was added. Cs2CO3 (1.14 mmol) was 
introduced within the mixture and toluene (2 mL) was added. The mixture was heated to 
80 °C under stirring, then was cooled to room temperature, diluted with diethyl ether, 
filtered, and concentrated. The crude product that was obtained was purified by column 
chromatography to obtain the desired adduct. 
Ethyl-2-(naphthylamino)benzoate 4. Procedure a: starting from 1-bromonaphthalene 
and ethyl-2-amino-benzoate. Reaction time: 17 hours. Silver foam, quantitative yield. 
Molecular formula: C19H17NO2. Molecular Weight: 291.34 g/mol. Rf = 0.47 
(cyclohexane/ethyl acetate 98:2). Eluent for chromatography: firstly only cyclohexane, 
then cyclohexane/ ethyl acetate from (98:2) to till (9:1). 1H NMR (300 MHz, CDCl3) δ 
9.85 (br s, 1H, NH, exchangeable with D2O), 8.10-8.13 (m, 1H, ArH), 8.05 (dd, J1 = 7.8 
Hz, J2 = 1.2 Hz 1H, ArH), 7.88-7.91 (m, 1H, ArH), 7.71 (d, J = 7.8 Hz, 1H, ArH), 7.45-
7.55 (m, 4H, ArH), 7.22-7.27 (m, 1H, ArH), 6.96 (dd, J1 = 8.7 Hz, J2 = 0.9 Hz, 1H, 
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ArH), 6.73 (dt, J1 = 7.8 Hz, J2 = 1.2 Hz, 1H, ArH), 4.43 (q, J = 7.2 Hz, 2H, CH2), 1.45 
(t, J = 7.2 Hz, 3H, CH3) ppm. 
Ethyl-2-(3-methoxy-1-naphthylamino)benzoate 4a. Procedure a: starting from 16a and 
ethyl-2-aminobenzoate. Reaction time: 18 hours. Yellow oil, 71% yield. Molecular 
formula: C20H19NO3. Molecular Weight: 321.37 g/mol. Rf = 0.62 (cyclohexane/ethyl 
acetate 9:1). Eluent for chromatography: cyclohexane/ethyl acetate (9:1). 1H NMR (300 
MHz, CDCl3) δ 9.98 (br s, 1H, NH, exchangeable with D2O), 8.08 (d, J = 8.1 Hz, 2H, 
ArH), 7.79 (d, J = 8.1 Hz, 1H, ArH), 7.50 (t, J = 8.1 Hz, 1H, ArH), 7.28-7.41 (m, 3H, 
ArH), 7.19 (d, J = 8.4 Hz, 1H, ArH), 7.02 (d, J = 2.4 Hz, 1H, ArH), 6.79 (t, J = 7.8 Hz, 
1H, ArH), 4.45 (q, J = 6.9 Hz, 2H, CH2), 3.95 (s, 3H, OCH3), 1.47 (t, J = 6.9 Hz, 3H, 
CH3) ppm. 
Ethyl-2-(4-methoxy-1-naphthylamino)benzoate 4b. Procedure b: starting from 20 and 
17. Reaction time: 18 hours. Yellow oil, 98% yield. Molecular formula: C20H19NO3. 
Molecular Weight: 321.37 g/mol. Rf = 0.40 (cyclohexane/ethyl acetate 98:2). Eluent for 
chromatography: cyclohexane/ethyl acetate (98:2). 1H NMR (300 MHz, CDCl3) δ 9.49 
(br s, 1H, NH, exchangeable with D2O), 8.30 (d, J = 8.8 Hz, 1H, ArH), 8.06-7.89 (m, 
2H, ArH), 7.55-7.42 (m, 2H, ArH), 7.37 (d, J = 8.2 Hz, 1H, ArH), 7.15 (t, J = 8.4 Hz, 
1H, ArH), 6.82 (d, J = 8.3 Hz, 1H, ArH), 6.64 (t, J = 7.6 Hz, 1H, ArH), 6.58 (d, J = 8.6 
Hz, 1H, ArH), 4.41 (q, J = 7.1 Hz, 2H, CH2), 4.03 (s, 3H, OCH3), 1.44 (t, J = 7.1 Hz, 
3H, CH3) ppm. 
Ethyl-3-(naphthylamino)benzoate 6. Procedure a: starting from 1-bromonaphthalene 
and ethyl-3-amino-benzoate. Reaction time: 17 hours. Yellow-brown oil, 83% yield. 
Molecular formula: C19H17O2. Molecular Weight: 291.34 g/mol. Rf = 0.39 
(cyclohexane/ethyl acetate 9:1). Eluent for chromatography: cyclohexane/ethyl acetate 
(95:5). 1H NMR (300 MHz, CDCl3) δ 8.01 (dd, J1 = 8.4 Hz, J2 = 1.2 Hz, 1H, ArH), 7.88 
(dd, J1 = 7.0 Hz, J2 = 2.5 Hz, 1H, ArH), 7.67-7.71 (m, 1H, ArH), 7.36-7.64 (m, 6H, 
ArH), 7.28 (t, J = 8.1 Hz, 1H, ArH), 7.12 (ddd, J1 = 8.1 Hz, J2 = 2.4 Hz, J3 = 1.0 Hz, 
1H, ArH), 6.06 (br s, 1H, NH, exchangeable with D2O), 4.36 (q, J = 7.1 Hz, 2H, CH2), 
1.38 (t, J = 7.1 Hz, 3H, CH3) ppm. 
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Ethyl-3-(3-methoxy-1-naphthylamino)benzoate 6a. Procedure a: starting from 16a and 
ethyl-3-aminobenzoate. Reaction time: 18 hours. Yellow oil, 85% yield. Molecular 
formula: C20H19NO3. Molecular Weight: 321.37 g/mol. Rf = 0.36 (cyclohexane/ethyl 
acetate 9:1). Eluent for chromatography: cyclohexane/ethyl acetate (98:2). 1H NMR 
(300 MHz, CDCl3) δ 7.91 (d, J = 8.1 Hz, 1H, ArH), 7.74-7.78 (m, 2H, ArH), 7.63 (dt, J1 
= 7.5 Hz, J2 = 1.2 Hz, 1H, ArH), 7.46 (dt, J1 = 7.8 Hz, J2 = 1.2 Hz, 1H, ArH), 7.21-7.36 
(m, 3H, ArH), 7.04 (d, J = 2.4 Hz, 1H, ArH), 6.90 (d, J = 2.1 Hz, 1H, ArH), 6.13 (br s, 
1H, NH, exchangeable with D2O), 4.37 (q, J = 6.9 Hz, 2H, CH2), 3.90 (s, 3H, OCH3), 
1.39 (t, J = 7.2 Hz, 3H, CH3) ppm. 
Ethyl-3-(4-methoxy-1-naphthylamino)benzoate 6b. Procedure a: starting from 16b and 
ethyl-3-aminobenzoate. Reaction time: 40 hours, 40% yield. Procedure b: starting from 
21 and 17. Reaction time: 24 hours, 94% yield. Brown oil. Molecular formula: 
C20H19NO3. Molecular Weight: 321.37 g/mol. Rf = 0.25 (cyclohexane/ethyl acetate 
9:1). Eluent for chromatography: cyclohexane/ethyl acetate (9:1). 1H NMR (300 MHz, 
CO(CD3)2) δ 8.13-8.16 (m, 1H, ArH), 7.88-7.91 (m, 1H, ArH), 7.33-7.40 (m, 3H, ArH), 
7.21-7.26 (m, 1H, NH, exchangeable with D2O; 2H, ArH), 7.10 (t, J = 7.8 Hz, 1H, 
ArH), 6.82-6.25 (m, 2H, ArH), 4.14 (q, J = 7.2 Hz, 2H, CH2), 3.91 (s, 3H, OCH3), 1.17 
(t, J = 7.2 Hz, 3H, CH3) ppm. 
Ethyl-3-(4-((tert-butoxycarbonyl)amino)-1-naphthylamino)benzoate 6g. Procedure a: 
starting from 18g and ethyl-3-aminobenzoate. Reaction time: 18 hours. Silver foam, 
83% yield. Molecular formula: C24H26N2O4. Molecular Weight: 406.47 g/mol. Rf = 
0.40 (cyclohexane/ethyl acetate 8:2). Eluent for chromatography: cyclohexane/ethyl 
acetate (8:2). 1H NMR (300 MHz, CD3OD) δ 8.09 (d, J = 8.1 Hz, 1H, ArH), 8.02 (d, J = 
8.4 Hz, 1H, ArH), 7.41-7.57 (m, 5H, ArH), 7.34 (d, J = 8.1 Hz, 1H, ArH), 7.25 (t, J = 
7.8 Hz, 1H, ArH), 7.11 (dd, J1 = 8.1 Hz, J2 = 2.1 Hz, 1H, ArH), 4.30 (q, J = 7.2 Hz, 2H, 
CH2), 1.55 (s, 9H, CH3), 1.34 (t, J = 7.2 Hz, 3H, CH3) ppm. 
Ethyl-3-(5-((tert-butoxycarbonyl)amino)-1-naphthylamino)benzoate 6h. Procedure a: 
starting from 18h and ethyl-3-aminobenzoate. Reaction time: 18 hours. Foam, 85% 
yield. Molecular formula: C24H26N2O4. Molecular Weight: 406.47 g/mol. Rf = 0.33 
(cyclohexane/ethyl acetate 8:2). Eluent for chromatography: cyclohexane/ethyl acetate 
(8:2). 1H NMR (300 MHz, CDCl3) δ 7.82 (d, J = 7.5 Hz, 1H, ArH), 7.70 (d, J = 8.4 Hz, 
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1H, ArH), 7.59 (t, J = 1.8 Hz, 1H, ArH), 7.47-7.54 (m, 2H, ArH), 7.26-7.35 (m, 3H, 
ArH), 7.18 (t, J = 7.5 Hz, 1H, ArH), 7.02 (dd, J1 = 8.4 Hz, J2 = 1.5 Hz, 1H, ArH), 6.83 
(br s, 1H, NH, exchangeable with D2O), 6.02 (br s, 1H, NH, exchangeable with D2O), 
4.26 (q, J = 6.9 Hz, 2H, CH2), 1.48 (s, 9H, CH3), 1.28 (t, J = 6.9 Hz, 3H, CH3) ppm. 
1-(N-phenylamino)naphthalene 7. Procedure a: starting from 1-bromonaphthalene and 
aniline. Yellow-brown oil, 34 % yield. Molecular formula: C16H13N. Molecular Weight: 
219.28 g/mol. Rf = 0.58 (cyclohexane/ethyl acetate 9:1). Eluent for chromatography: 
firstly only cyclohexane and then cyclohexane/ ethyl acetate (95:5). 1H NMR (300 
MHz, CDCl3) δ 8.04 (dd, J1 = 7.2 Hz, J2 = 2.1 Hz, 1H, ArH), 7.89 (dd, J1 = 7.2 Hz, J2 = 
2.1 Hz, 1H, ArH), 7.59 (dd, J1 = 7.2 Hz, J2 = 2.1 Hz, 1H, ArH), 7.40-7.53 (m, 4H, 
ArH), 7.26-7.31 (m, 2H, ArH), 7.00-7.03 (m, 2H, ArH), 6.94 (t, J1 = 7.2 Hz, J2 = 1.2 
Hz, 1H, ArH), 5.95 (br s, 1H, NH, exchangeable with D2O) ppm. 
 
General procedure for the ester hydrolysis to obtain (naphthylamino)benzoic acid 
derivates (3, 3a,b, 5, 5a,b,g,h).  
To a solution of the suitable ethyl-(naphthylamino)-benzoate (0.15 mmol) in 2 mL 
of THF/EtOH (1:1), 1M NaOH (0.375 mmol) was added [152]. The resulting mixture 
was refluxed for a period of time different for each substrate. The solvent was 
evaporated and then water (2 mL) was added. The aqueous phase was firstly washed 
with diethyl ether in order to purify the reaction mixture from the unreacted starting 
material, and then treated with 1N HCl (0.5 mL). The acid was extracted with ethyl 
acetate (3x1 mL), then the organic phase was dried over anhydrous sodium sulfate and 
the solvent was evaporated under reduced pressure. The crude was purified by flash 
chromatography eluting dichloromethane/methanol (95:5) to afford the desired 
derivates. 
2-(naphthylamino)benzoic acid 3. Starting compound: compound 4. Reaction time: 60 
minutes. Yellow oil, 98 % yield. Molecular formula: C17H13NO2. Molecular Weight: 
263.29 g/mol. Rf = 0.39 (dichloromethane/methanol 95:5). 1H NMR (300 MHz, 
CO(CD3)2) δ 10.09 (br s, 1H, NH, exchangeable with D2O), 8.07-8.09 (m, 2H, ArH), 
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7.95-7.97 (m, 1H, ArH), 7.77 (d, J = 7.5 Hz, 1H, ArH), 7.51-7.58 (m, 4H, ArH), 7.33 (t, 
J = 8.7 Hz, 1H, ArH), 6.97 (d, J = 8.7 Hz, 1H, ArH), 6.78 (t, J = 7.5 Hz, 1H, ArH) ppm. 
2-(3-methoxy-1-naphthylamino)benzoic acid 3a. Starting compound: compound 4a. 
Reaction time: 30 minutes. Yellow foam, quantitative yield. Molecular formula: 
C18H15NO3. Molecular Weight: 293.32 g/mol. Rf = 0.34 (dichloromethane/methanol 
95:5). 1H NMR (300 MHz, CO(CD3)2) δ 10.15 (br s, 1H, NH, exchangeable with D2O), 
7.96 (d, J = 8.4 Hz, 1H, ArH), 7.85 (d, J = 8.4 Hz, 1H, ArH), 7.71 (d, J = 8.1 Hz, 1H, 
ArH), 7.35 (t, J = 7.2 Hz, 1H, ArH), 7.20-7.244 (m, 2H, ArH), 7.08 (d, J = 2.1 Hz, 1H, 
ArH), 6.99-7.02 (m, 2H, ArH), 6.68 (d, J = 7.2 Hz, 1H, ArH), 3.80 (s, 3H, OCH3) ppm. 
2-(4-methoxy-1-naphthylamino)benzoic acid 3b. Starting compound: compound 4b. 
Reaction time: 90 minutes. Oil, 53 % yield. Molecular formula: C18H15NO3. Molecular 
Weight: 293.32 g/mol. Rf = 0.54 (dichloromethane/methanol 95:5). 1H NMR (300 
MHz, CO(CD3)2) δ 9.72 (br s, 1H, NH, exchangeable with D2O), 8.25-8.34 (m, 1H, 
ArH), 8.03 (dd, J1 = 8.0 Hz, J2 = 1.6 Hz, 1H, ArH), 7.89-7.96 (m, 1H, ArH), 7.48-7.58 
(m, 2H, ArH), 7.44 (d, J = 8.1 Hz, 1H, ArH), 7.23 (dt, J1 = 8.4 Hz, J2 = 1.6 Hz, 1H, 
ArH), 7.01 (d, J = 8.1 Hz, 1H, ArH), 6.69 (t, J = 7.6 Hz, 1H, ArH), 6.58 (d, J = 8.5 Hz, 
1H, ArH), 4.07 (s, 3H, OCH3) ppm. 
(naphthylamino)benzoic acid 5. Starting compound: compound 6. Reaction time: 60 
minutes. Oil, 96 % yield. Molecular formula: C17H13NO2. Molecular Weight: 263.29 
g/mol. Rf = 0.25 (dichloromethane/methanol 95:5). 1H NMR (300 MHz, CD3OD) δ 
8.12 (d, J = 7.5 Hz, 1H, ArH), 7.82 (d, J = 7.5 Hz, 1H, ArH), 7.64 (s, 1H, ArH), 7.32-
7.52 (m, 6H, ArH), 7.20 (t, J = 7.5 Hz, 1H, ArH), 7.08 (d, J = 7.5 Hz, 1H, ArH) ppm. 
3-(3-methoxy-1-naphthylamino)benzoic acid 5a. Starting compound: compound 6a. 
Reaction time: 40 minutes. Oil, 96 % yield. Molecular formula: C18H15NO3. Molecular 
Weight: 293.32 g/mol. Rf = 0.19 (dichloromethane/methanol 95:5). 1H NMR (300 
MHz, CO(CD3)2) δ 7.95 (d, J = 8.4 Hz, 1H, ArH), 7.64-7.68 (m, 2H, ArH), 7.59 (br s, 
1H, NH, exchangeable with D2O), 7.41-7.44 (m, 1H, ArH), 7.14-7.33 (m, 4H, ArH), 
6.91 (d, J = 2.1 Hz, 1H, ArH), 6.87 (d, J = 2.1 Hz, 1H, ArH), 3.74 (s, 3H, OCH3) ppm. 
3-(4-methoxy-1-naphthylamino)benzoic acid 5b. Starting compound: compound 6b. 
Reaction time: 60 minutes. Oil, 73 % yield. Molecular formula: C18H15NO3. Molecular 
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Weight: 293.32 g/mol. Rf = 0.16 (dichloromethane/methanol 95:5). 1H NMR (300 
MHz, CO(CD3)2) δ 8.25–8.31 (m, 1H, ArH), 7.99-8.07 (m, 1H, ArH), 7.45-7.55 (m, 3H, 
ArH), 7.36-7.42 (m, 2H, ArH), 7.34 (bs, 1H, NH, exchangeable with D2O), 7.24 (t, J = 
7.8 Hz, 1H, ArH), 7.00 (dd, J = 8.1, J2 = 1.6 Hz, 1H, ArH), 6.96 (d, J = 8.2 Hz, 1H, 
ArH), 4.04 (s, 3H, OCH3) ppm. 
3-(4-((tert-butoxycarbonyl)amino)-1-naphthylamino)benzoic acid 5g. Starting 
compound: compound 6g. Reaction time: 30 minutes. Silver foam, quantative yield. 
Molecular formula: C22H22N2O4. Molecular Weight: 378.42 g/mol. Rf = 0.17 
(dichloromethane/methanol 95:5). 1H NMR (300 MHz, CD3OD) δ 8.09 (d, J = 7.8 Hz, 
1H, ArH), 8.01 (d, J = 8.7 Hz, 1H, ArH), 7.42-7.59 (m, 5H, ArH), 7.32 (d, J = 8.1 Hz, 
1H, ArH), 7.24 (t, J = 7.8 Hz, 1H, ArH), 7.10 (dq, J1 = 7.8 Hz, J2 = 1.5 Hz, 1H, ArH), 
1.54 (s, 9H, CH3) ppm. 
3-(5-((tert-butoxycarbonyl)amino)-1-naphthylamino)benzoic acid 5h. Starting 
compound: compound 6h. Reaction time: 30 minutes. Green-brown oil, 79 % yield. 
Molecular formula: C22H22N2O4. Molecular Weight: 378.42 g/mol. Rf = 0.20 
(dichloromethane/methanol 95:5). 1H NMR (300 MHz, CO(CD3)2) δ 8.19 (br s, 1H, 
NH, exchangeable with D2O), 7.84 (d, J = 8.7 Hz, 1H, ArH), 7.75 (dd, J1 = 6.9 Hz, J2 = 
3 Hz, 1H, ArH), 7.70 (d, J = 7.5 Hz, 1H, ArH), 7.58 (t, J = 2.1 Hz, 1H, ArH), 7.55 (br s, 
1H, NH, exchangeable with D2O), 7.28-7.40 (m, 4H, ArH), 7.20 (t, J = 7.5 Hz, 1H, 
ArH), 712 (dq, J1 = 8.1 Hz, J2 = 1.2 Hz, 1H, ArH), 1.39 (s, 9H, CH3) ppm. 
 
General procedure for the demethoxylation of α,β-naphthol-methyl ethers. 
To a solution of the proper methoxynaphthalene (0.180 mmol) in dry 
dichloromethane (2 mL), BBr3 (1M in dichloromethane, 0.945 mmol) was added 
dropwise under N2 [151]. The reaction takes place at room temperature for all the 
synthesized compounds except from 5c and 3d, indeed, the starting solution was firstly, 
cooled at -78°C and BBr3 was carefully added dropwise to the reaction mixture. After 
20 minutes, the resulting solution was warmed to room temperature and the stirring was 
continued for further 3 hours. The reaction was then quenched at 0°C with water (4 
mL), and extracted with ethyl acetate (3x2 mL). The combined organic phases were 
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washed with brine (3x1 mL) and dried over anhydrous sodium sulfate. The subsequent 
filtration and evaporation of the organic solvent provide a crude product, which was 
purified by flash chromatography eluting firstly with dichloromethane/methanol (95:5) 
and then with dichloromethane/ methanol (8:2) to afford the final naphthol. 
2-(3-hydroxy-1-naphthoyl)benzoic acid 1c. Starting compound: compound 1a. Reaction 
time: 60 minutes. Foam, 6 % yield. Molecular formula: C18H12O4. Molecular Weight: 
292.29 g/mol. Rf = 0.10 (dichloromethane/methanol 95:5). 1H NMR (300 MHz, 
CD3OD) δ 8.78 (d, J = 8.1 Hz, 1H, ArH), 8.01 (dd, J1 = 7.5 Hz, J2 = 1.2 Hz, 1H, ArH), 
7.64-7.72 (m, 3H, ArH), 7.37-7.53 (m, 3H, ArH), 7.28 (d, J = 2.4 Hz, 1H, ArH), 7.00 
(d, J = 2.7 Hz, 1H, ArH) ppm. 
2-(3-hydroxy-1-naphthylamino)benzoic acid 3c. Starting compound: compound 3a. 
Reaction time: 30 minutes. Brown-purple foam, 90 % yield. Molecular formula: 
C17H13NO3. Molecular Weight: 279.29 g/mol. Rf = 0.17 (dichloromethane/methanol 
95:5). 1H NMR (300 MHz, CO(CD3)2) δ 10.00 (br s, 1H, exchangeable with D2O), 7.95 
(dd, J1 = 7.8 Hz, J2 = 1.5 Hz, 1H,ArH), 7.81 (d, J = 8.4 Hz, 1H, ArH), 7.59 (d, J = 7.8 
Hz, 1H, ArH), 7.10-7.32 (m, 4H, ArH), 6.99 (d, J = 8.4 Hz, 1H, ArH), 6.93 (d, J = 1.8 
Hz, 1H, ArH), 6.67 (t, J = 7.5 Hz, 1H, ArH) ppm. 
2-(4-hydroxy-1-naphthylamino)benzoic acid 3d. Starting compound: compound 3b. 
Reaction time: 90 minutes. Dark foam, 98 % yield. Molecular formula: C17H13NO3. 
Molecular Weight: 279.29 g/mol. Rf = 0.18 (dichloromethane/methanol 95:5). 1H NMR 
(300 MHz, CO(CD3)2) δ 9.66 (br s, 1H, exchangeable with D2O), 9.14 (br s, 1H, 
exchangeable with D2O), 8.25-8.38 (m, 1H, ArH), 8.02 (dd, J1 = 8.0 Hz, J2 = 1.7 Hz, 
1H, ArH), 7.85-7.94 (m, 1H, ArH), 7.43-7.58 (m, 2H, ArH), 7.32 (d, J = 7.9 Hz, 1H, 
ArH), 7.22 (dt, J1 = 7.7 Hz, J2 = 1.5 Hz, 1H, ArH), 6.98 (d, J = 8.0 Hz, 1H, ArH), 6.67 
(t, J = 7.5 Hz, 1H, ArH), 6.55 (d, J1 = 8.3 Hz, 1H, ArH) ppm. 
3-(3-hydroxy-1-naphthylamino)benzoic acid 5c. Starting compound: compound 5a. 
Reaction time: 210 minutes. Oil, 91 % yield. Molecular formula: C17H13NO3. Molecular 
Weight: 279.29 g/mol. Rf = 0.17 (dichloromethane/methanol 95:5). 1H NMR (300 
MHz, CO(CD3)2) δ 7.93 (d, J = 8.0 Hz, 1H, ArH), 7.67 (s, 1H, ArH), 7.53-7.60 (m, 2H, 
81 
 
ArH), 7.40-7.44 (m, 1H, ArH), 7.22-7.30 (m, 3H, ArH, NH, exchangeable with D2O), 
7.08-7.14 (m, 1H, ArH), 6.96 (d, J = 2.7 Hz, 1H, ArH), 6.81 (s, 1H, ArH) ppm. 
3-(4-hydroxy-1-naphthylamino)benzoic acid 5d. Starting compounds: compound 5b. 
Reaction time: 60 minutes. Yellow oil, 89 % yield. Molecular formula: C17H13NO3. 
Molecular Weight: 279.29 g/mol. Rf = 0.13 (dichloromethane/methanol 95:5). 1H NMR 
(300 MHz, CO(CD3)2) δ 8.99 (br s, 1H, exchangeable with D2O), 8.26-8.32 (m, 
1H,ArH), 7.96-8.03 (m, 1H, ArH), 7.44-7.51 (m, 3H, ArH), 7.33-7.39 (m, 1H, ArH), 
7.18-7.30 (m, 2H, ArH), 6.90-6.99 (m, 2H, ArH) ppm. 
 
General procedure for Boc-deprotection to obtain the corresponding amines as 
hydrochloride salts (5e,f).  
To an ice-cold solution of the proper tert-butyl-naphthylcarbamate (632 mg, 1.67 
mmol) in dry 1,4-dioxane (1 mL), HCl (4M in 1,4-dioxane, 1 mL) was added dropwise, 
under N2. The reaction was stirred at room temperature for 24 hours. After completion 
of the reaction, monitored by TLC, diethyl ether was added to the reaction mixture and 
it was stirred. After cooling at 0°C, the formed precipitate was collected by filtration, 
washed with cold diethyl ether and dried to afford hydrochloride acid salt of compound 
5e or 5f. 
3-(4-amino-1-naphthylamino)benzoic acid hydrochloride 5e. Starting compound: 
compound 5g. Foam, 58 % yield. Molecular formula: C17H14N2O2  HCl. Molecular 
Weight: 314.77 g/mol. 1H NMR (300 MHz, CD3OD) δ 8.33 (d, J = 9 Hz, 1H, ArH), 
7.94 (d, J = 9 Hz, 1H, ArH), 7.72-7.78 (m, 2H, ArH), 7.66 (t, J = 8.1, 1H, ArH), 7.57-
7.60 (m, 1H, ArH), 7.49 (d, J = 8.1 Hz, 1H, ArH), 7.33-7.40 (m, 3H, ArH) ppm. 
3-(5-amino-1-naphthylamino)benzoic acid hydrochloride 5f. Starting compound: 
compound 5h. Foam, 66 % yield. Molecular formula: C17H14N2O2  HCl. Molecular 
Weight: 314.77 g/mol. 1H NMR (300 MHz, CD3OD) δ 8.28 (dd, J1 = 8.1 Hz, J2 = 1.2 
Hz, 1H, ArH), 7.66 (t, J = 2.1 Hz, 1H, ArH), 7.49-7.63 (m, 6H, ArH), 7.34 (t, J = 7.8 
Hz, 1H, ArH), 7.26 (dq, J1 = 8.1 Hz, J2 = 1.2 Hz, 1H, ArH) ppm. 
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